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Abstract  
The purpose of this study was to evaluate the Edmonton Obesity Staging System (EOSS) 
approach as a tool for the identification of obesity-related health risk. Using 20 years of follow-
up data from the Coronary Artery Risk Development in Young Adults (CARDIA) study 
(N=5115; age 18-34), trajectory modelling analysis was used to identify distinct clusters of 
individuals following similar patterns of obesity using modified EOSS criteria. The final model 
acquired through the Proc Traj macro suggests that there are 4 distinct EOSS stage-increase 
trajectories. After adjusting for covariates, individuals in the medium risk trajectory were twice 
more likely to follow protein consumption guidelines (OR=2.08 95% CI=1.18-3.65), 47% less 
likely to be black (0.53, 0.37-0.76), 43% less likely to have a history of dieting (0.57, 0.37-0.86), 
and were also less likely to be either occasional (0.51, 0.29-0.9) or frequent (0.25, 0.14-0.45) 
weight cyclers when compared to the highest risk trajectory.  
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1. Extended Introduction 
1.1 General Obesity Issues 
Obesity has been a constant, growing problem over the past several decades, affecting all 
segments of the population, regardless of sex, ethnicity, education and socio-economic status. It 
has become a global pandemic, with recent estimates suggesting that more than 500 million 
individuals are obese worldwide, and that this number is only going to get higher.1 It is projected 
that by 2030, there may be as many as 1.12 – 1.35 billion obese individuals globally.2 3 Recent 
evidence from the United States shows that obesity is now, in fact, the country's leading cause of 
preventable death.4 What’s worse, this obesity-mortality relationship strengthens with age and 
with obesity severity.5 6 Not surprisingly, the American Medical Association (AMA) has recently 
(2013) voted to recognize obesity as a disease in the hopes of being able to better combat the 
obesity epidemic.7 Some believe that this may lead to more resources being devoted toward 
researching and treating obesity, a problem that costs the American healthcare system almost 
$190 billion annually.8 Others are more skeptical, suggesting that “medicalizing” obesity by 
declaring it a disease, would lead to more reliance on costly drugs and surgery without a similar 
investment in primary prevention through lifestyle modification. 9 Canada has also experienced a 
rise in obesity, with some research suggesting that the rates have exceeded 30% in half of the 
provinces, and that they are still expected to rise. 10 The prevalence of obesity in children has 
tripled over the past 30 years, with about 12-13% school-aged children being obese.11   
The World Health Organization (WHO) defines obesity as an abnormal or excessive fat 
accumulation that presents a risk to health.12 Multiple action plans and policy declarations have 
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been put into place to promote healthy diets and active lifestyles, to little benefit. Obesity is not 
just a simple weight gain; it can reduce life expectancy, lead to other illnesses, serious health 
complications, and eventual death.13 Many of the leading causes of death also related to obesity, 
and it is known to increases the risk of hypertension, diabetes, coronary heart disease (CHD), 
dyslipidemia, stroke, liver & gall bladder disease, osteoarthritis, sleep apnea (respiratory 
problems) and some cancers (endometrial, breast, and colon).14 15 Beyond these physical 
conditions, obesity has also been associated with depression and social stigmatization, with some 
research also identifying a reciprocal relationship (i.e. depression may be predictive of obesity).16 
17 18  
Obesity is influenced by numerous factors, including sex, race, age, genes and socio-
economic-status (SES), making it difficult to determine the true “cause”.19 The recently 
developed obesity systems map shows hundreds of pathways to obesity that form a complex web 
of overlapping and reinforcing causal factors.20 An argument can be made that the obesity 
epidemic is a product of globalization. Improvements in transportation, agriculture and labour-
saving technologies and various trade agreements have contributed to a marked increase in food 
availability by virtue of an increased production of high-calorie processed foods and the rapid 
expansion of fast- food chains and multinational food conglomerates.21 22 Combined with an 
overall decrease in total daily physical activity levels due to urbanization, mechanization, better 
transportation, and other changes in the physical and social environment have contributed to the 
observed rise in body weight.20 These rapid changes in everyday life have magnified the overall 
burden of obesity and contributed to ensuing obesity-related health complications.  
Unfortunately, due to the complex, multi- factorial nature of this disease, there is no universal 
treatment for obesity. Despite evidence in support of low-calorie diets, healthy eating plans, 
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increased physical activity, psychological counselling, peer-support groups, and weight- loss 
surgery, among others, individualised weight loss is challenging.23 In Canada, the lack of good 
cost-effectiveness studies of obesity prevention and management programs has hampered the 
public health decision making process.24 Specifically, obese individuals generally have much 
higher costs associated with hospitalizations and day procedures and overall cause a greater 
strain on the economic system, with almost 40% greater hospitalization costs when compared to 
normal-weight adults.25 The accurate identification of ‘obesity’ and those individuals who are 
likely to suffer the consequences of their excess weight is an important consideration within the 
universal healthcare system in Canada. Compounding the issue of obesity identification is the 
overall inaccuracy of the current anthropometric classification systems such as waist 
circumference (WC), and to a greater extent, Body Mass Index (BMI) especially considering the 
frequent use of self- reported data in major health studies.  
1.2 BMI Application and Limitations 
Most of the currently employed anthropometric approaches to the measurement of 
obesity are based on simple clinical measures. These often come in the form of weight, height, 
BMI and waist circumference (WC), and while they are quick and simple to use on the 
population level, they often lack the detail necessary for clinical decision making. Alternatively, 
there exist a number of very accurate quantitative measurements of body composition (e.g. 
bioelectrical impedance analysis, dual energy X-ray absorptiometry, CT scans, magnetic 
resonance spectroscopy, quantitative magnetic resonance (QMR), etc.), but their complexity, 
accessibility and cost remain a significant hindrance in their application in a day-to-day clinical 
setting.26 They are nevertheless very useful in research settings especially for scientists 
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examining anti-obesity interventions due to their overall accuracy in measuring whole-body fat 
and lean mass in humans.27 These will be discussed in greater detail in later sections.  
When considering obesity on a global scale, it quickly becomes apparent that these 
techniques are not very useful for population- level interventions especially in low-income or 
developing countries. In most cases however, BMI is used as the predominant measure of 
obesity. This is not surprising, because BMI is very easy to use, can be quickly self-measured, 
and is very useful for clinical studies or any sort of population/sample comparative analysis. 
BMI has also been shown to be strongly correlated with body fat percentage in many different 
populations.28 29 30 The BMI cut-offs have been accepted worldwide and are integrated into the 
Canadian clinical practice guidelines as follows; a BMI of 18.5 - 24.9 kg/m2 is normal, 25.0 – 
29.9 kg/m2 is overweight and a BMI ≥ 30.0 kg/m2 is considered obese.31  
At the same time, there are multiple serious limitations to BMI, especially when looking 
at sex, age and racial/ethnic differences at the individual level. Women tend to have more body 
fat than men at any given BMI, with this relationship especially noticeable between young girls 
and boys.32 33 34 A higher amount of muscle mass in men contributes to a heavy-set body size, 
which could create a false-positive classification of obesity, but with presumably a low level of 
fat mass and subsequent health risk.35 Similarly, racial/ethnic differences in the body fat-BMI 
relationship have been observed, 36 37 leading to the development of race-specific BMI 
guidelines. 38 39 BMI might also underestimate obesity because of loss of muscle mass, lean 
tissue and bone density due to aging.40 41 42 Finally, BMI is unable to discriminate between lean 
and fat tissue, and ignores medical conditions that affect height or body shape. The inability of 
BMI to distinguish between fat mass and fat free mass could contribute to either an under- or 
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over-estimation of the prevalence of obesity, depending on the population in which it is 
employed. As such, being unable to account for varied body frame (and the training-associated 
abdominal fat loss and muscle gain) size makes BMI a poor tool of choice for the study of some 
professional athletes and body-builders or even individuals in weight management programs.  
To better illustrate this difference, in recent years, researchers have begun to use DXA 
scans (Dual-energy X-ray absorptiometry) scans to measure body composition and fat content 
with much higher overall accuracy.43 While relatively expensive to use, it has nevertheless been 
very useful in clinical body composition analysis, particularly in identifying normal-weight but 
obese individuals.44 These DXA scans can reveal that 2 individuals with the same BMI can have 
drastically different health and fitness profiles.45 Because of these and other limitations, the 
accuracy and sensitivity of BMI has often been challenged, especially in the light of recent 
research into the ‘fit- fat’ paradox.46 Specifically, research suggests that not all obese individuals 
are at increased health risk.47 There is also evidence that obesity is independently associated with 
reduced cardiovascular fitness and that individual factors (health behaviours, adverse health 
conditions, race/ethnicity, income etc.) can play a role in its improvement. 48 Simply put, while 
useful in population level-analysis, the current anthropometric classification system is based on 
simple clinical measures, such as BMI have limited application for individual patients.                            
1.3 Alternative Obesity Measures - Waist Circumference 
Waist circumference (WC) is another tool that has been used separately or in conjunction 
with the BMI for the measurement of obesity. It is the most straightforward, inexpensive way 
(simple measuring tape) of measuring abdominal obesity, irrespective of BMI. As of 2012, the 
National Institute of Health (NIH) WC cut-offs have been used as the standard method for WC 
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measurement in Canada.49 According to these criteria, men with a WC greater than 102 cm (>40 
in.) and women with a WC greater than 88 cm (>35 in.) are considered high risk. Despite the 
stronger relationship between abdominal obesity and health risk (than BMI and health risk), 
variation in the WC measurement site has contributed to imprecision in its use44 50  
In addition, there are also some other key limitations. Besides the above-mentioned 
standardization issue, NIH suggests that at BMIs higher than 35, waist circumference has little 
additional predictive power of disease risk above the one predicted by BMI. 51 52 Some studies go 
a step further saying that WC is either impossible or useless altogether for measuring obesity risk 
in severely obese individuals.53 In addition to this, it can altogether miss those that carry a large 
amount of fat in their hips. For instance, individuals with the same WC have been found to have 
significantly different levels of visceral fat, and this difference may contribute to the 
underestimation of obesity.54 Complicating the relationship further is the fact that physical 
activity levels, ethnicity, genetics, medical history and diet preferences may also play a role in 
the variability of visceral fat.55 However, it is fair to mention that carrying fat in other parts of 
the body is not as dangerous as having a large proportion of abdominal fat. 56 Similar to what was 
is seen with BMI, there are multiple age and ethnic/racial-related differences in fat distribution 
that can have an effect on WC and subsequent health-risk measures. 32 57 58 For example, the 
International Diabetes Federation (IDF) uses ethnic-specific criteria to define abdominal obesity 
for the metabolic syndrome.59 Making things more difficult is the fact that there are no similar 
guidelines for children; an important limitation, considering the increasing world-wide child 
obesity rates and the recognized importance of early-age intervention in global obesity 
prevention.60 61       
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1.4 Alternative Obesity Measures – Waist-to-Hip Ratio 
 Another common measure used to evaluate abdominal obesity and to estimate the risk of 
developing obesity-related health problems is the waist to hip ratio (WHR). Much of the value of 
this ratio is that increased gluteofemoral fat mass reduces an individual’s cardiovascular and 
metabolic risk.62 Similar to WC, there are 2 accepted ways of measuring WHR. The World 
Health Organization states that the waist circumference  should be measured at the approximate 
midpoint between the lower margin of the last palpable rib and the top of the iliac crest. 63 Hip 
circumference is to be measured around the widest portion of the buttocks, ensuring that the tape 
is parallel to the floor.60 The NIH suggests that WC at the top of the iliac crest, while other 
independent researchers have taken the measurements at the point of the minimal waist.46 64 
While most studies find no significant difference between the different types of measurement  
protocols, controversies remain and the issues are especially evident when comparing self-
reported WHR numbers.65 66 The exact cut-offs for abdominal obesity are also in debate with 
WHO suggesting that they should be 0.9 for males and 0.85 for females, while the National 
Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) states that it is 1.0 and 0.8 for 
men and women respectively.67  68 Overall, WHR is considered the simplest measure of fat 
distribution. It requires no special training, knowledge or equipment and can be taken at home 
and is the least invasive way of measuring own body composition levels. It is directly tied to the 
concept of ‘body-shape’, and may better predict the development of cardiovascular-related health 
risk than BMI.69 70 71  Some also find that WHR is a better predictor of overall mortality, 
especially of circulatory-related mortality.72 Suffice to say, central obesity seems to be directly 
associated with mortality as demonstrated by a recent systematic review by a group of Mayo 
Clinic researchers.73  
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 Here again, however, waist-to-hip ratio suffers from most of the key limitations seen in 
WC. Similar to WC, the main problem with WHR is that its accuracy decreases with increasing 
levels of obesity.74 From a research standpoint the main concern then, is whether or not WHR 
actually adds anything new to the relationship between health risk and increased abdominal fat. 
In this regard, comparisons between WHR and WC are inconclusive. On the one hand, WHR 
takes into account the hip fat distribution that WC cannot measure; however, it is harder to 
measure, requiring 2 accurate measurements instead of 1, making WC the better choice in many 
settings.75 It is also more difficult to interpret because changes in WHR can be the result of an 
increase in abdominal fat (WC), lower levels of lower body lean mass, or a the reverse 
combination.76 77 78 As a result, an individual with a high waist circumference may benefit from 
weight loss exercise and diets, while an individual with small hips might benefit from resistance 
training to build up body mass. WHR sometimes fails to account for the different effects of 
adipose tissue in the abdominal and gluteofemoral regions. 79 Ethnic-specific differences have 
also been identified, with some studies showing that African-Americans have a lower visceral fat 
mass compared to that of individuals of European-descent.80 Some studies find no difference 
whatsoever in metabolic risk factors or cardiovascular disease when comparing WC and WHR81 
82 83 while others show that it is superior for the assessment of mortality risk in the elderly, than 
either WC or BMI.84 Other researchers question whether there is any additional value to 
measuring BMI and WHR, given the large inter- individual (e.g. sex, ethnic, etc.)  and that that 
the associations between overall obesity, central adiposity, and adverse health outcomes may 
vary due to sex, as well ethnic and racial differences. 85 86  
Finally, looking at WHR alone is often not enough to gauge the obesity-related risks 
because due to the nature of the ratio calculations, two individuals with the same WHR can have 
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drastically different BMIs. For example, a 250 pound, 6 foot male weightlifter can have a WHR 
of 1.0, with a BMI of 33.9. At the same time a 160 pound, 6 foot non-athletic male can also have 
a WHR of 1.0 but at the same time he will have a BMI of only 21.7. Just by looking at the WHR 
numbers, these two individuals seem identical, and both are at borderline obesity-related risk. 
The weightlifter, in fact is also obese, but that does not necessarily mean that they are unhealthy, 
unfit or at risk in any way. This is especially important to consider in light of the recent research 
into the ‘metabolically healthy but obese’ phenomenon. 87  
1.5 Alternative Obesity Measures – BVI, Skinfold Tests, SAD 
 This section will briefly cover a couple of additional, less frequently employed measures 
of adiposity including the body volume index (BVI), skinfold thickness tests and the sagittal 
abdominal diameter (SAD). First, the body volume index has recently been proposed as an 
alternative to BMI to assess body volume distribution to measure obesity and individual health 
risk.88 Introduced early in 2000, BVI is an application that can be used in a 3D Full Body 
Scanner, to analyze abdominal area, and serve as an early warning system to help identify those 
individuals that are particularly at risk of heart disease, stroke, and diabetes. 89 The scanner itself 
is a seven-foot booth that has 16 sensors and 32 cameras and takes a virtual image of the 
person’s shape using white light. The researchers behind BVI note that BMI was never intended 
to be an individual tool for obesity assessment, and that BVI will take each patient’s own body 
shape and lifestyle factors into account when measuring obesity-related risks.88 Pilot studies have 
shown much promise, including the ability to track changes occurring over time but further 
studies are necessary to determine possible uses for BVI scans in combating obesity. 90 Others 
suggest that while BVI is a more accurate obesity-measurement tool, it is also very expensive 
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and somewhat difficult to use.91 While greater accuracy, consistency and speed of delivery (a full 
scan is estimated to take just 6 seconds to complete) are all major advantages of BVI, the 
combination of some software skills, the size of the scanner and the associated costs might make 
it unreasonable and unlikely to be used in family practices or small medical clinics. 92    
 Second, skinfold thickness tests have been employed for decades and are used to estimate 
body fat percentage by measuring the fat under the skin also known as the subcutaneous adipose 
tissue. A special caliper is used to pinch the skin and measure the fat underneath it at specific 
sites of the body. There are 7 specific locations on the body and these measurements are 
combined to calculate percent body fat. Some advantages of skinfold thickness tests include their 
portability and convenience, their usefulness in assessing body composition, and the overall low 
costs and labour requirements.93 94 They are also very reliable indices of regional fatness and are 
sometimes even used to predict whole body composition.94 There are however some limitations 
to skinfold tests, mostly in caliper technique and in the way the measurements are taken. 
Skinfold tests require more skill and practical experience than other simple measures of obesity; 
to minimize measurement error and variability, standardized training is therefore required.95 96 
Similar to other discussed obesity measurement tools, skinfold measurements are difficult to 
obtain for many obese subjects because fat tissue can actually exceed the limits of the caliper or 
the clinicians are simply unable to grasp a double thickness of tissue. 97 Finally, because skinfold 
measurements only calculate subcutaneous fat they might not be very effective in measuring 
overall body fat percentage, especially in lean, athletic individuals. In light of the above, the 
usefulness and applicability of skinfold thickness tests in clinical, school, or community settings 
is somewhat limited.97    
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 Another relatively recent measure of central obesity is the sagittal abdominal diameter 
(SAD), a measure of the distance from the back to the upper abdomen. It is very simple to 
measure in either supine or standing position; has minimal associated costs, requires little to no 
prior training or expertise and is highly reproducible. It can also be measured at any point 
between the lower rib margin and the superior anterior iliac crest, giving it some flexibility and 
improving ease of use.98 Studies show that SAD is a good predictor of CHD, increased metabolic 
risk, and insulin resistance in overweight and obese individuals.99 99 100 An increase in SAD has 
been associated with an increased risk of sudden death, independent of BMI level and known 
CVD-related risk factors.101 However, no standardized SAD cut-offs exist, making direct 
comparisons.102 103 More importantly however, it is unclear whether SAD measures provide any 
clear advantage over waist circumference or BMI alone 104 105 106 or whether any of the results 
can be replicated in a larger population.101 103 107 More research and larger prospective studies are 
needed to compare the clinical utility of SAD, and its potential effectiveness over other 
anthropometric measurements.108   
1.6 Alternative Obesity Measures – Obesity Research Tools 
 Due to their expense and the high degree of technical skill required for their use, some of 
the most precise tools for obesity assessment are currently limited to the research environment. 
These include bioelectrical impedance, underwater weighting (Hydrodensitometry), Air-
Displacement Plethysmography, Computerized Tomography (CT) and Magnetic Resonance 
Imaging (MRI). Most of these measuring tools are very good predictors of obesity and in most 
cases are actually better than the previously-mentioned anthropometric tools, especially at the 
individual level. However, they are all either time consuming, difficult to use or very expensive, 
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and in the case of CT and MRI, are rarely used outside of the research settings.20 Bioelectrical 
impedance analysis (BIA) estimates percent body fat by measuring resistance to the flow of a 
small electric current that gets passed through the body. Relatively small and inexpensive, it is 
nevertheless rarely used in population- level surveillance because of the quality of the different 
devices used, the types of measurements taken (location of fat is unknown), and the lack of 
information on its relevance to diverse ethnic groups.109 110 There are multiple different water-
based measurement tools, and while very accurate in calculating body density, they all share 
significant limitations (time consuming, lots of specialized equipment, requiring individual water 
submersion) that make them difficult to use outside of the research setting. 111 Air-Displacement 
Plethysmography is conceptually analogous to underwater weighting, except that it estimates the 
air pressure difference between empty and occupied air chambers.112 Unfortunately, while much 
more precise and easier to use than hydrodensitometry, the air chamber or “pod” is very 
expensive.94 Despite being very good methods for measuring obesity, the above-mentioned tools 
are nevertheless unlikely to ever be used in small clinical practices, schools or for personal, 
individual use. 
 From the above overview, it seems apparent that most of the anthropometric measures 
currently in use have very key limitations and are only useful and accurate enough when dealing 
with specific subsets of the population or when a combined measurement approach is employed. 
The measurement tools with most potential are rarely used outside of the research setting due to 
a combination of high costs, low availability and technical complexity. The lower cost methods 
tend to be unable to clearly outline the severity of health conditions, especially at an individual 
level. Furthermore, given that few individuals are able to successfully maintain their weight loss, 
the risk of ‘weight cycling’ on health must also be considered. 113 114 115 It is therefore apparent, 
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that alternative obesity screening tools are needed, if obesity treatment protocols are to be truly 
optimized. The following section will take an in-depth look into one such alternative screening 
tool, and examine its practicality and effectiveness as assessed to date.  
1.7 Edmonton Obesity Staging System - Overview 
 First introduced in 2009 by Sharma and Kushner, the Edmonton obesity staging system 
(EOSS) is a novel clinical and functional staging system that allows clinicians to describe the 
psychological, quality of life, and morbidity and functional limitations associated with excess 
body fat.116 It aims to refine existing screening strategies by incorporating both physical and 
mental dimensions of health, in order to more accurately identify the morbidity and health risks 
of a given individual.117 This clinical staging system was created in the hopes of both improving 
obesity prognosis and guiding subsequent obesity treatments in individuals. Using BMI 
“obesity” cut-offs as its basis, EOSS is also able to provide information on disease comorbidities  
and functional limitations not seen in any other classification systems.    
 Simply put, EOSS is able to evaluate how “sick” an individual is, and then provide 
treatment steps or suggestions. Urgency of intervention and patient prioritization for 
interventions can be considered as additional outcomes of the system. This prioritizing can 
ensure not only a greater degree of accuracy in identifying individuals that would benefit from 
specific surgery or procedures, but also reducing weight times, procedural expenditures and 
increasing the overall effectiveness of any given health intervention. For example, recent studies 
on weight loss procedures illustrate the fact that EOSS might be a good tool to use to redefine 
indications for bariatric surgery in obese individuals and to assist in the triage of very high-risk 
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individuals.118 119. The potential improvements in both patient selection and resource allocation 
are reasons enough to further investigate EOSS as a clinically-valid obesity-management tool.  
 The proposed staging system has a simple structure consisting of medical history, clinical 
and functional assessments and additional or routine diagnostic check-ups. A complete summary 
of EOSS and its related components can be found in Sharma and Kushner (2009) or at Dr. Arya 
Sharma’s website120. In general, EOSS consists of 5 stages (0-4) that are organized in an 
increasing level of severity. Each stage lists the necessary stage- inclusion criteria, followed by 
possible solutions or suggestions as to what to do for that particular stage (Appendix B, Table 
1). To be classified as “Stage 0”, an individual would need to be obese (BMI > 30 kg/m2), and 
show no medical, mental or functional problems. This individual would fit the ‘metabolically 
healthy but obese’ profile as mentioned previously. The EOSS level of each individual would be 
based on the highest-stage risk factor present (Appendix B, Table 1). Therefore, a medically 
and psychologically healthy obese individual that nonetheless demonstrates moderate functional 
limitations (i.e. difficulty moving up and down the stairs, arm pain after moderate exertion, 
trouble running, etc.) would be considered stage 2 since his functional limitation is the highest 
level limitation available. From the examples above, the risk management plan for a stage 0 
individual would focus primarily on preventing further weight gain and identifying the reasons 
behind the current increased body weight. For the functionally limited stage 2 individual, the 
focus would be on trying to first improve his functional problem and then implement some sort 
of a weight-reducing program. It may very well be that the patient’s functional disability is 
preventing him or her from moving, exercising or losing weight in general. The obvious 
exception here is stage 4 individuals who would most likely be palliative patients with terminal 
illnesses or other severe (most likely untreatable) conditions. For instance, not only would 
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weight reduction be the least of the problems for cancer patients, but it might actually be 
severely detrimental to their health (since cancer commonly results in weight loss).121  
These management steps, in concordance with current anthropometric classification 
systems (i.e. BMI) would give clinicians a detailed snapshot of the patient’s health and provide 
them with an outline of some possible treatment pathways.  The lack of scientific studies looking 
at obesity risk-factor management make this an important topic of study, especially considering 
the multi- factorial nature of obesity development. The effective implementation of a risk-
identification system as EOSS can not only identify these high-risk individuals but may also 
theoretically help to alleviate the financial and the social burdens associated with obesity. Thus, a 
longitudinal approach is essential to identify factors that could contribute to obesity in the early 
stages of adulthood, and that could play a role in future weight gain or weigh fluctuation. To this 
end, the study objectives were as follows: 
1.8 Study Research Objectives 
Objective 1: To identify trajectories of EOSS stages (1 to 3) over 20 years of follow-up in the 
CARDIA dataset.  
Objective 2: To determine characteristics of groups at high-risk of obesity-related health risk in 
both overweight/obese trajectories and EOSS trajectories.  
1.9 CARDIA study summary 
 To better evaluate EOSS as a potential risk identification-prediction tool, it is essential to 
look at a longitudinal study to see long-term changes and trends of specific conditions or any 
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other variables. Beginning in 1985-6, The Coronary Artery Risk Development in Young Adults 
(CARDIA) is a long-running (26 years +) longitudinal US study that looks at the development of 
heart disease in black and white individuals in 4 different centers across the US. 122 It is 
sponsored by the National Heart, Lung, and Blood Institute of the National Institutes of Health 
(NHLBI) and had follow-up examinations during 1987-1988 (Year 2), 1990-1991 (Year 5), 
1992-1993 (Year 7), 1995-1996 (Year 10), 2000-2001 (Year 15), 2005-2006 (Year 20), and 
2010-1011 (Year 25).123 Due to due to NHLBI data access limitations, only data for 20 years will 
be used in this paper. The study had a relatively low drop-out rate with about 72% of the sample 
still available for examination at year 20 (Appendix B, Figure 1). The recruitment and 
distribution of respondents was reviewed and pooled by age, sex, education (high school or less 
and more than high school) and race, to get an approximately equal number of participants in 
each category and in each examination center. The 4 examination centres were located in 
Birmingham, AL; Chicago, IL; Minneapolis, MN; and Oakland, CA. Each of the examination 
centres were chosen for the availability of a representative biracial population. There were 5115 
individuals in the study at baseline. After merging all the data, 3690 participants remained. Most 
of the individuals that were excluded were individuals who dropped out of the study before it 
finished (N=1400). Others were dropped due to duplicate patient IDs (N=20) and missing 
height/weight variables (N=5) which were excluded due to the inability to measure BMI.       
 While the aims and objectives of each follow-up have varied, all the collected data is 
believed to factor in or be related to heart disease. Data has been collec ted on a wide range of 
measurements including metabolic factors (blood pressure, lipids, cholesterol, glucose, etc.), 
physical measurements (weight, height), substance use (alcohol and tobacco), diet and exercise 
patterns, medication history, behavioral and psychological variables and certain co-morbidites 
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(medical and family history of known conditions and diseases). Although some additional 
conditions (i.e. atherosclerosis), and advanced diagnostic scans were also employed at specific 
examinations (i.e. abdominal CT scan during Year 25), there were largely irrelevant to the study 
objectives.  
In CARDIA, it is possible to track changes in health and lifestyle habits (i.e. disease, 
exercise, smoking patterns, etc.) across early-to-mid adulthood and this is key because the 
CARDIA cohort, born 1955-1968, has been influenced substantially by the obesity epidemic at 
ages younger than participants in other established NHLBI cohorts.127 Multiple observations of 
the same individual can also provide the researchers with a better idea of the direction of the 
causal relationship and to some extent, explain the strength of the statistical association. 124 The 
CARDIA database contains the majority of the variables used in the EOSS definition, making it 
an excellent way to test both the effectiveness of EOSS, and the usefulness of the trajectory 
modelling approach in evaluating obesity and obesity-related comorbidities.   
1.10 Trajectory Modelling Overview 
 First introduced in 1993 by Nagin and Land as a tool to analyze the co ncept of a 
“criminal career”, trajectory modelling has come to be widely used by other disciplines and 
especially in clinical practices where it is used to study the etiology and developmental course of 
various diseases, patient response to clinical treatments, and other applications.125 Trajectory 
modeling is a type of group-based Bayesian, semi-parametric model that is used with 
longitudinal data. It allows researchers to group data based on different parameters and 
distributions.126 Trajectory models can also work with time-varying covariates and can account 
for different types of data including count, binary, psychometric scales and normal 
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distributions.127 The calculated trajectory shows the probability of group membership over time. 
These groups are helpful in identifying high-risk individuals or other specific subpopulations and 
are also able to approximate data for missing individuals (with 2 or more years). Unlike other 
types of trajectory modelling, group-based trajectory modelling makes no innate assumptions 
about the population distribution, and rather serves as a statistical device for approximating the 
unknown distribution of trajectories across population members. 128 Another advantage is that it 
can be used to facilitate causal inference especially when random assignment to treatment 
condition is not possible.129  
In the current thesis, a custom proc Traj macro was used to create the trajectories in SAS 
(9.3). One major advantage of Proc Traj is that it uses all the available inputted data for both the 
outcome and the risk factors. An intercept and a regression coefficient is then estimated for each 
of the outcome groups in the model. The Wald test is used to test the significance of the 
estimated intercept and regression coefficient, and the final model is chosen based on the 
Bayesian Information Criterion (BIC). Developed by Gideon E. Schwarz in 1978, the BIC is the 
standard approach for model fitting and selection. 130 BIC introduces a penalty to balance the 
increase in the likelihood with the number of parameters. The best model is the one with the 
smallest negative BIC in the most complex model. For more information on BIC, see Jones 
(2001).131 For this study, data was tested with 2, 3, 4, 5 models to identify the best model ‘fit’ on 
the basis of Bayesian stats and posterior probability to determine the final number of trajectories. 
With a well-defined model each individual in the dataset had a high probability of belonging to 
one particular group and a low probability of belonging to each of the others. The final model 
illustrates the probability of each individual belonging to a particular EOSS stage trajectory 
(low-risk, stable, high-risk) change associated with that particular trajectory. The corresponding 
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EOSS stage definitions were created based on Appendix B, Table 1 and with reference to 
available EOSS-related research papers. Please refer to Appendix B, Figure 2 for a short 
example of a Proc Traj Syntax.         
1.11 Manuscript Foreword  
 Given the multifactorial nature of obesity, no single factor is responsible for its global 
rise. Very few studies have looked at obesity trends and the associated prevalence of obesity-
related conditions as complex patterns of health status over an extended period of time. 131 In 
particular, potential obesity co-morbidities and covariates such as the psychological, socio-
functional and emotional factors and their effect on lifetime obesity trends have not been 
adequately studied. The following paper will demonstrate an example of how EOSS can be used 
to study obesity in a longitudinal setting. The Coronary Artery Risk Development in Young 
Adults (CARDIA) study will be used for this analysis. Patterns of overweight and obesity will be 
scrutinized using trajectory modelling analysis, and compared against the development of 
comorbidities as they relate to EOSS stage framework. A longitudinal dataset such as CARDIA 
therefore allows for examination of individual risk factors, and clusters of conditions, while also 
contributing to an improved understanding of the ways in which individuals move through 
different EOSS stages through the subsequent check-ups.  
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2. 1 Introduction 
Worldwide it is estimated that 1.3 billion individuals are overweight, more than 500 
million of whom are obese.132 Increased food availability, combined with an increase in caloric 
intake as well as a reduction in physical activity have made obesity a global pandemic.133 This 
trend is especially noticeable in Canada, where a recent Obesity in Canada report revealed that 
approximately one in four adults are obese.134 There are many known causes of obesity and 
obesity-related diseases but there is no universal treatment. This problem is compounded by the 
by the inaccuracy of the current anthropometric classification systems such as waist 
circumference (WC), and to a greater extent, Body Mass Index (BMI).  
Commonly employed anthropometric measures are based on simple clinical measures. 
Weight, height, and waist circumference (WC) are simply not precise or accurate enough to 
account for many health risks and comorbidities. The often-used BMI, for example, does not 
take into account a person’s body fat content, and is very unreliable in athletes, pregnant women, 
the very young or very old and ignores medical conditions that affect height or body shape.135 
The accuracy of these measures has often been challenged, especially considering recent 
research into the ‘fit-fat’ paradox,46 bone and fat mass studies,35 and individual factors such as 
health behaviours, adverse health conditions, race/ethnicity, and income.48 Other anthropometric 
tools are available but are either somewhat inaccurate and cumbersome to use or cost 
prohibitive.,26 and it has become clear that other approaches are necessary to optimize the 
treatment and management of obesity-related risk factors.  
Proposed by Sharma and Kushner in 2009, the Edmonton Obesity Staging System 
(EOSS) aims to refine existing screening strategies by incorporating both physical and mental 
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dimensions of health, in order to more accurately identify the health risks of a given 
individual.117 At its core, EOSS is a clinical staging system that complements anthropometric 
measures and, serves as a tool for determining prognosis and guiding obesity treatment.136 Very 
few studies have looked at obesity trends and the associated prevalence of obesity-related 
conditions over an extended period of time.133 137 138 Furthermore, the psychological, socio-
functional and emotional factors of obesity and obesity-related diseases have not been adequately 
assessed in a longitudinal setting. This aim of this study is to therefore to identify trajectories of 
EOSS stages (1 to 3) over 20 years of follow-up in the CARDIA dataset and to determine 
characteristics of groups at high-risk of obesity-related health risk.              
2.2 Methods 
2.2.1 Participants  
The Coronary Artery Risk Development in Young Adults (CARDIA) is a U.S. 
longitudinal cohort study that examines the development of heart disease in black and white 
individuals and that is sponsored by the National Heart, Lung, and Blood Institute of the 
National Institutes of Health (NHLBI).124 It began in 1985-86 and consisted of 5115 black and 
white, relatively healthy individuals of both sexes, aged 18-30 years (2 age groups: 18-24 and 
25-30). Individuals were pooled to allow for an equal representation across all age-sex-race 
groups in each of the 4 examination centres across the United States. Due to NHLBI data access 
limitations, only data for 20 years was used in this study. After merging the follow-up data and 
removing individuals with multiple missing variables (N=1 425), the final sample consisted of 
3690 participants with baseline and follow-up information. An additional 508 people were 
removed due to key missing response variables during the whole-model computations leaving a 
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total of 3182 individuals for the final, year 20 analysis. Because of EOSS exclusion criteria, only 
individuals with the Body Mass Index (BMI) of 30 kg/m2  were used for the EOSS portion of the 
analysis, resulting in 365 obese individuals being available at baseline. Baseline Demographic 
variables included gender, age, ethnicity and level of education [those with no highschool 
education, only a highschool diploma, a college or university degree, and those that have a 
Master’s degree and above (including professional degrees)].  
2.2.2 Key medical variables 
EOSS Components 
Data has been collected at baseline and each follow-up on a wide range of measurements 
including metabolic factors (blood pressure, lipids, cholesterol, glucose, etc.), physical 
measurements (height, weight), substance use (alcohol and tobacco), diet and exercise patterns, 
behavioral and psychological variables and certain comorbidities (medical and family history of 
known conditions and diseases). Phlebotomy followed standard protocols, with blood being 
drawn in a completely upright position and frozen (-700C) immediately after drawing. BMI 
classification was based on the World Health Organization (WHO) cut-offs and was measured 
with the standard formula: weight in kilograms divided by the square of the height in metres 
(kg/m)139. Specific details on each EOSS variable if provided in section 3.3.   
Other Measures 
The updated NCEP ATP III (2004) cut-offs were used to identify participants with the 
metabolic syndrome (MetS)140, and Canadian Cardiovascular Society worksheets were used to 
calculate the Framingham risk scores (FRS).141 142 See Appendix B, Table 2 for a detailed 
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overview of the MetS and FRS definition used. Physical activity intensity was subsequently 
estimated based on the Centre for Disease Control and Prevention (CDC) physical activity 
guidelines.143 Individuals were asked questions about the number of times they had taken part in 
specific activities over the past year, and these scores were later added to create a single 
“physical activity intensity score”. Males were considered “inactive” if the total score was less 
than 336 units, “moderately active” if they scored between 336 and 610 units and “active” if they 
had above 610. For females, the cut-offs were: < 192, between 192 and 400 and > 400 for 
inactive, moderately active and active, respectively.  
Anyone who ate at a fast food place more than twice per week was considered a frequent 
consumer of fast food.144 Individuals were considered occasional weight cyclers if they reported 
losing and regaining more than 10 pounds at least 1-4 times throughout their lives.145 Those that 
reported losing weight more than 5 times were considered frequent weight cyclers (Appendix C, 
Table 3). Meeting dietary guidelines for protein, fat and carbohydrate consumption was 
calculated as a percentage based on the daily intake energy requirements as outlined in the 
Dietary Guidelines for Americans 2010 report. Individuals had to have consumed between 45-
65% carbohydrate, 10-35% protein and 20-35% fat daily to meet the corresponding 
macronutrient guidelines.146  
2.2.3 EOSS 
Similar to other papers written on this topic, a modified EOSS definition was used to 
account for missing variables.9 Most importantly, the lack of any physical/functional variables 
meant that the functional subset of EOSS was omitted entirely. Furthermore, in order to maintain 
a reasonable sample size and to avoid loss of power, some variables were grouped together by 
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type (i.e. all types of cancers were just grouped under “cancer”) or by category (i.e. “mental 
disorders” was a broad definition and included personality disorders, depressions, psychotic 
problems, etc.). The criteria used for EOSS categorization was based on the highest-stage risk 
factor present as shown in Table 1. For example, an individual with no mental disorders, 
physical impairments and normal- level fasting glucose and blood pressure but who has  
hypercholesterolemia would be categorized as EOSS stage 2, based on the most highest risk 
factor present. A detailed description of the EOSS criteria is provided in Sharma and Kushner 
(2009).116 147  
2.2.4 Statistical Analysis 
Data are presented as means with standard deviations (SD) or as % proportions. ANOVA 
and Fisher’s Exact Chi-squared analysis was performed to test for baseline differences between 
the 4 different trajectory groups. For ease of comparison with the obese population, underweight, 
normal and overweight individuals were all categorized as “non-obese”. Trajectory modelling 
was used to identify distinct clusters of individuals following similar patterns o f obesity 
calculated over time.130 Proc Traj, a modified SAS macro was used for this analysis.127 This 
macro is not part of the base SAS program, and was downloaded from the Jones’ main 
webpage.148 The Bayesian Information Criterion (BIC) was used for model selection. The model 
with the most complexity and the lowest BIC value was chosen as the optimal model.149 
Multinomial logistic regression was then used to develop a character profile of each EOSS 
trajectory. Additional factors (diet history, calories consumed, drinking habits, exercise patterns, 
education level, and metabolic syndrome) were compared between the different EOSS stages and 
these were adjusted for age, sex, smoking status and exam year using forward step-wise 
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selection. Additional covariates included fast- food consumption frequency and weight-cycling 
history; however, due to insufficient follow-up data, only baseline data was used for these 2 
variables. SAS 9.3 was used for all statistical calculations with statistical significance set at p 
<0.05.     
2.3 Results 
The baseline distribution of all continuous & categorical variables for all obese 
individuals is shown in Table 2. In total, there were 365 obese individuals at baseline, which 
accounted for about 10% of the overall sample. The EOSS stage categorization was as follows: 
3.3% were stage 0 (N=12), 38.9% stage 1 (N=142), 54.5% stage 2 (199) and 3.3% (N=12) were 
stage 3. In the trajectory model at baseline, there were 6 individuals in the no-risk (group 1), 227 
individuals in the medium risk (group 2), 93 in high risk (group 3) and 39 in chronic risk (group 
4) groups. Compared with the chronic risk individuals, medium risk individuals were slightly 
older, heavier, were likely to be male and moderate drinkers, have higher SBP and DBP but 
lower HDL levels (all p < 0.05). They were also a lot less likely to have heart problems (p < 
0.01). In order to prevent the loss of power, all EOSS-related trajectory calculations were not 
stratified due to the uneven sex (27.9% male) and ethnic (26.0% white) distribution as well as an 
overall low sample size in the obese sample. 
To better understand and evaluate the diagnostic and differential capabilitie s of EOSS, 
prevalence of MetS and Framingham Risk Scores were used for comparative purposes (Figure 
1). Overall, there were only 0.3% (N=1) of individuals with MetS amongst the obese sample at 
baseline. This number however increased at a somewhat consistent rate, with MetS being 
prevalent in almost 50% of all obese individuals by year 20. Unfortunately, due to missing data, 
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no MetS or Framingham scores could be calculated for the first follow-up at examination year 2. 
Nevertheless, EOSS demonstrated a similar pattern of risk growth and disease prevalence 
tendencies to both METS and FRS, especially on an individual stage basis. For example, EOSS 
stage 3 (which includes CHD incidence) risk growth was very similar in nature to the observed 
Framingham CHD risk pattern. Likewise, Stage 2 has a pattern similar to the observed METS 
trend for both the obese and the normal portions of the sample (Figure 1).           
Trajectory analysis identified 4 distinct clusters of individuals progressing through EOSS 
stages over 20 years of follow-up (Figure 2). Individuals in group 3 had one or more EOSS-
related risk factors at baseline that contributed to a steep increase in risk over the next 10 years. 
Groups 2 and 4 show similar growth patterns with baseline risk factors playing a deciding role in 
group membership and subsequent development of health risk. About 14% of the individuals 
(group 4) exhibited high risk factors at baseline that worsened with time, whereas 4% of the 
individuals (N=54) showed a surprising decrease in overall EOSS stage risk. All 4 of the 
observed trajectories tended to plateau at around age 40 (5th follow-up, year 15 of the study, 
Figure 1).  
All comparative analysis were performed against the 4th (most at-risk, most severe) 
trajectory group. Overall, group 4 was the highest risk group, primarily because it had a much 
higher proportion of EOSS stage 3 individuals (52.9% p<0.0001). In addition to this a greater 
proportion of black individuals were present in the higher-risk groups 3 and 4 (68.7% and 60.8% 
respectively, data not shown) Compared to 4th trajectory, individuals in the 1st group were much 
less likely to be frequent weight cyclers (OR=0.34 95% CI=0.12-0.99). However, this 
relationship disappeared with subsequent adjustments. Individuals in group 2 were much more 
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likely to be male (OR=2.16 95% CI=1.47-3.17), be moderate drinkers (OR=1.92 95% CI=1.16-
3.19), and follow established protein guidelines (OR=2.44 95% CI=1.41-4.22). They were also 
much less likely to be black (OR=0.63 95% CI=0.44-0.88), be on a diet at the time of the initial 
survey (OR=0.39 95% CI=0.25-0.63), have “ever” dieted (OR=0.4 95% CI=0.28-0.56), and to be 
occasional (OR=0.4 95% CI=0.23-0.69) or frequent (OR=0.2 95% CI=0.11-0.35) weight cyclers. 
Finally, group 3 individuals were more likely to be male (OR=2.33 95% CI=1.48-3.67), black 
(OR=1.58 95% CI=1.03-2.44), slightly older (OR=1.06 95% CI=1.003-1.13), and follow 
established protein guidelines (OR=3.28 95% CI=1.41-7.64) than the high-risk group 4 
individuals. These crude ratio analyses are illustrated in Appendix C, Table 6. No sex or race 
interactions were observed.  
Table 3 illustrates the final adjusted model of group membership. After adjusting each 
individual factors for each other, individuals in group 2 were 47% less like ly to be black 
(OR=0.53 95% CI=0.37-0.76), 43% less likely to have a history of dieting (OR=0.57 95% 
CI=0.37-0.86), 49% less likely to be occasional weight cyclers (OR=0.51 95% CI=0.29-0.9) and 
75% less likely to be frequent weight cyclers (OR=0.25 95% CI=0.14-0.45). They were also 
about two times more likely to follow protein consumption guidelines (OR=2.08 95% CI=1.18-
3.65) as compared to the group 4, high-risk individuals. Individuals in group 3 were almost 2.7 
times more likely to be male (OR=2.69 95% CI=1.64-4.41), 80% more likely to be black 
(OR=1.83 95% CI=1.16-2.88), be slightly older [In the 25-30 age group (OR=1.08 95% 
CI=1.02-1.15)] and about 2.8 times more likely to follow protein guidelines than group 4 
individuals.  
2.4 Discussion 
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Results from the current study provide preliminary insight into patterns of obesity-related 
health risk amongst obese individuals over 20 years of follow-up. In this sample of black and 
white men and women, weight history, dieting practice and macronutrient consumption have all 
shown to influence EOSS stage progression, and this knowledge can help clinicians better 
identify and manage high-risk individuals. Overall, EOSS helped identify critical risk- factors 
that place individuals in group 4 at a much greater obesity-related risk. More specifically, a 
higher proportion of these high-risk individuals reported cancer, coronary heart disease (CHD), 
and severe physical limitations during exercise.     
Due to the initial sample collection criteria and study protocols, the vas t majority of the 
participants were very healthy at baseline, and only 10% (of the initial sample) had obesity. 
Comparatively, data from NHANES shows a 13.6% prevalence of obesity among U.S. adults 
aged 20-29, in 1988-94 150 and 36% in 2012.151 In CARDIA the prevalence of obesity increased 
from 10% to about 29.6% over the 20 years of the study (Figure 1). Individuals who were 
healthy at the start of the study, have over time, worsened their overall health to a level similar to 
that of the modern US population.  
In general, other studies show that weight increases with age and that SES also plays a 
role in this relationship, meaning that our observed increase in obesity can, at least, be partially 
explained through a natural aging mechanism. 152 The finding that a greater proportion of black 
individuals were present in the higher-risk groups 3 and 4 is also supported by literature on the 
variation in health risk and obesity patterns amongst different ethnic groups. 153 154 Recent 
evidence suggests that compared with white men and women, black individuals have almost 50% 
higher obesity rates with black women having the highest prevalence of obesity. 155 156 Education 
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did not play a role in group membership despite significant baseline differences between normal 
and obese individuals (X2=12.64 p < 0.01), and could be potentially explained by the fact that 
only healthy individuals were selected for the study. Due to the longitudinal nature of the study, 
individuals were able to improve their education over time (Appendix C, Table 3), thus limiting 
the initial differences; furthermore, evidence on the relationship between obesity and education 
is conflicting, with some studies showing strong inverse relationships, while others pointing to 
factors such as SES, income, social inequality, and built environment interactions (proximity to 
parks, gyms, healthcare facilities, etc.) as the more significant determinants of obesity. 157 158  
Other lifestyle factors also had a significant effect on group memberships. Specifically, 
group 2 (medium-risk) individuals were less likely to be weight cyclers and to have a history of 
diets while at the same time being much more likely to follow the established protein 
consumption guidelines. Similarly, group 3 (high-risk) individuals were also much more likely to 
follow the protein guidelines. After adjusting for exercise and all of the available dietary factors, 
most of the unadjusted and/or baseline associations disappeared. Both smoking and physical 
activity were not found to be significant predictors of group membership, despite evidence of a 
role in weight gain and BMI trajectories.9 159 The physical activity definition used may not be 
optimal, which could be the reason why no effect was observed. Alternatively PA can actually 
exert influence through the EOSS variables themselves.  
Weight cycling played a major role and was one of the variables that stayed constant 
even after multiple adjustments. In particular, individuals fitting the more stable, low change 
group 2 (medium-risk) trajectory were less likely to weight cycle than the other groups (Figure 
2). Knowing the health risk associated with weight cycling, and the overall tendency of weight 
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cyclers to gain even more weight,160 161 points to the reason as to why the stable individuals were 
the least likely to weight cycle. Coincidentally, group 2 (medium-risk) individuals are also the 
ones who were less likely to report ever having been on a diet, providing a further reason why 
their EOSS stage gain trajectory remained relatively unchanged over time. While fast food 
consumption, and adherence to fat and carbohydrate guideline differences were all non 
significant at baseline and after all subsequent adjustments, adherence to protein consumption 
guidelines was a very significant predictor of group membership, with both group 2 and 3 
showing a much higher adherence rate than the high-risk group 4. This finding is in line with 
select research that suggests an increase in dietary protein (from 15% to 30% combined with a 
reduction of fat) can result in a significant weight loss.162 Other studies show a variable effect, 
ranging from stable weight-maintenance to a loss of visceral fat with an increased protein-based 
diet.163 When taken together, these findings may partially explain why lower-risk individuals 
were less likely to change EOSS stage and had higher adherence to protein consumption 
guidelines.  
We used the Framingham risk score and MetS criteria to further evaluate the CARDIA 
sample and to see how it relates to other established risk assessment strategies in the ge neral 
population. MetS prevalence increased from 0.03 % at baseline to ~19% after 20 years, yielding 
similar prevalences to other studies (22%).164 For the obese, MetS prevalence increased from 
0.3% - 42%, significantly lower than other national health studies (65%).165 The Framingham 
risk score at year 20, when the individuals were roughly 45 years old, was overall lower than the 
reported risk scores for middle-aged adults in other US based studies. Specifically, one study that 
analyzed the NHANES III survey discovered that about 72.6% (age-adjusted) of all participants 
without CHD had a 10-year risk for CHD of <10% and 11.9% with a risk between 10% to 
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20%.166 Comparatively, about 66.3% of our CARDIA sample had a CHD risk of <10% and 
about 18% were between 10% to 20%. Differences in sample inclusion and exclusion criteria, as 
well observed above average CHD prevalence rates could explain these observed disparities.   
2.5 Study Limitations 
The CARDIA study is a unique dataset that examines the development of heart disease in 
very healthy black and white US adults and is thus, not representative of the entire US 
population. On average, the sample was healthy at baseline, having no cancer and less than 1% 
diabetes and metabolic syndrome prevalence. Furthermore, because the dataset was not EOSS-
tailored, many individuals did not have complete data for all the necessary variables and in some 
cases had to be excluded due to vital missing data (i.e. BMI). The EOSS definition used had to 
be modified in order to account for insufficient or unavailable variables, and may therefore 
represent and over or underestimate of EOSS stage. This was particularly noticeable in year 2 of 
the study where a much higher proportion of individuals were classified as stage 0 due to 
multiple missing metabolic variables (Figure 2). Furthermore, to reduce power loss and prevent 
over-stratification, different types of the same disorder/condition were combined under 1 broad 
heading. For example, all cancer sites were combined in one broad category. All psychological 
conditions as well as all other health problems (that were not included in any of the other 
categories) were also grouped under the corresponding broad definitions, and no assumptions 
were made about the effect that each had on specific EOSS stage placement or trajectory 
memberships.  
2.6 Conclusion 
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Trajectory analysis has proven to be a very useful tool for testing the effectiveness of 
EOSS and for overall identification of obesity-related patterns and risk factors. Despite its 
theoretical nature, trajectory analysis was useful at predicting group differences in patterns of 
obesity-related health risk.  Trajectory modelling, combined with an EOSS-based approach can 
help identify individuals at risk and serve as a visual guide to treatment formation and 
implementation. Future research is necessary to evaluate the clinical aspects of EOSS, in an 
effort to optimize obesity-related health risk and our understanding of risk profiles across 
trajectory groups.           
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2.7 Appendix (Paper) 
Table 1: Edmonton Obesity Staging System breakdown 
Stage Stage description (Sharma & Kushner 2009) Modified definition* 
0 No apparent obesity-related risk factors, medical, 
psychopathological & functional limitations (no 
impairment of well being).   
No EOSS-relevant reported factors 
1 - Presence of obesity-related subclinical risk factors 
(borderline hypertension, impaired fasting glucose, 
elevated liver enzymes, etc.) 
- Mild Physical Symptoms (dyspnea on moderate 
exertion, occasional aches and pains, fatigue, etc.) 
- Mild obesity-related psychological symptoms 
and/or mild impairment of well being.   
- BP > 120/80 and < 139/89 mm HG 
- Fasting Glucose ≥ 100 and < 125 mg/100 
ml 
- Cholesterol ≥ 200 and < 240 mg/100 ml 
- Trig lycerides ≥ 150 and < 200 mg/100 ml 
- HDL < 60 mg/100 ml (Men), < 60 mg/100 
ml (Women) 
- Have being diagnosed or currently suffering 
from ANY mental d isorder.  
- Have medical problems that affect exercise 
ability to a minor extent (1/5 or 2/5) 
2 - Presence of established obesity-related 
comorbid ities requiring medical intervention (HTN, 
Type 2 Diabetes, sleep apnea, osteoarthritis, reflux 
diseases, polyscystic ovary syndrome, etc.)  
- Moderate obesity-related psychological symptoms 
(depression, eating disorder, etc.) 
- Moderate functional limitations in daily act ivities 
impacting quality of life  
- Diagnosed hypertension or taking 
hypertensive medication  
- BP > 140/90 mm HG 
- Fasting Glucose ≥ 125 mg/100 ml 
- Diagnosed hypercholesterolemia or taking  
cholesterol lowering medicat ion 
- Cholesterol ≥ 240 mg/100 ml 
- Diagnosed hypertriglyceridemia  
- Trig lycerides ≥ 200 mg/100 ml 
- HDL < 40 mg/100 ml (Men), < 50 mg/100 
ml (Women) 
- Being diagnosed AND currently suffering 
from mental disorders.  
- Additional medical p roblems (arthritis, gall 
bladder disease, ovary disease, etc.) 
- Have medical problems that affect exercise 
ability to a significant extent (3/5 or 4/5)  
- Diagnosed Diabetes 
3 - Significant obesity-related end-organ damage (heart 
failure, myocardial infarction, diabetic 
complications)  
- Significant psychopathology (major depression, 
suicide ideation) 
- Significant functional impairment (unable to work, 
perform tasks), functional limitations or impairment 
of well being.  
- Having being diagnosed with cancer 
- Having being diagnosed with coronary heart 
disease (CHD) 
- Have medical problems that affect exercise 
ability to a major extent (5/5)  
 
4 - Severe (potential end-stage) disabilit ies from 
obesity-related comorbidit ies 
- Severe psychopathology (disabling) 
- Severe functional limitations or impairment of well 
being. 
This stage was not examined as no relevant 
factors were available or reported 
 
* Based on available CARDIA data 
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Table 2: Distribution and significance of trajectory groups at baseline 
Continuous Variable Name Group 1:  No-
risk (N=6) 
Group 2: 
Medium Risk 
(N=227) 
Group 3:  High 
Risk (N=93) 
Group 4: 
Chronic Risk 
(N=39) 
Age (years) *  24.33 (4.46)  25.07 (3.62) 26.46 (3.39) 24.10 (3.86) 
Height (cm) 167.33 (4.67) 167.49 (9.34)  168.34 (9.51) 165.08 (9.43) 
Weight (lbs) *  225.23 (45.36) 213.63 (31.02) 213.46 (30.32) 198.96 (23.7) 
WC (cm) 100.04 (14.19) 95.67 (9.86) 94.60 (8.85) 91.91 (8.39) 
 BMI (KG/m
2
) 36.31 (5.50) 34.64 (4.22) 34.31 (4.44) 33.26 (2.72) 
SBP (mm Hg) *  109.0 (4.69) 113.96 (10.74) 113.0 (9.54) 108.67 (10.19) 
DBP (mm Hg) *  64.0 (3.85) 71.53 (8.59) 69.22 (8.58) 68.08 (7.70) 
Calories (kcal) 1989.5 (781.9) 2657.5 (1362.7) 2856.2 (1556) 2297.3 (971.26) 
Glucose (mg/dL)  87.83 (4.67) 83.6 (8.42) 84.44 (7.26) 83.87 (6.35) 
TG1 (mg/dL) 69.67 (29.23) 80.74 (36.85) 73.22 (39.63) 82.26 (44.23) 
HDL (mg/dL) 
+
 51.83 (13.66) 44.82 (9.91) 52.3 (10.46) 47.74 (9.83) 
Intensity (Exercise Units) 292.17 (240.9) 319.9 (253.0) 338.12 (262.7) 310.85 (204.3) 
Categorical Variable Name      
Male *   
Female 
0 (0%)              
6 (100%) 
63 (27.8%)      
164 (72.2%) 
33 (35.5%)         
60 (64.5%) 
6 (15.4%)           
33 (84.6%) 
Black  
White 
4 (66.7%)          
2 (33.3%)           
166 (73.1%)      
61 (26.9%) 
74 (79.6%)         
19 (20.4%) 
26 (66.7%)           
13 (33.3%) 
No Highschool Education      
Highschool                        
College or University 
0 (0%)               
5 (83.3%)           
1 (16.7%) 
23 (10.3%)    
150 (67.3%)    
50 (22.4%) 
6 (6.7%)          
53 (59.6%)      
30 (33.7%) 
3 (7.7%)         
26 (66.7%)       
10 (25.6%) 
No Drinking *                
Moderate                            
Heavy 
4 (66.7%)          
2 (33.3%)          
0 (0%) 
181 (79.7%)     
38 (16.7%)        
8 (3.6%)  
68 (73.1%)       
18 (19.4%)        
7 (7.5%)  
35 (89.7%)        
1 (2.6%)           
3 (7.7%)   
Non S moker                          
Former                                 
Current 
3 (50%)             
0 (0%)              
3 (50%) 
128 (56.9%)     
28 (12.4%)        
69 (30.7%)  
53 (57.6%)       
6 (6.5%)         
33 (35.9%)  
20 (54.1%)        
5 (13.5%)           
12 (32.4%)   On a Diet                                 
Not on a Diet 
5 (83.3)             
1 (16.7) 
175 (84.95%)      
31 (15.05%) 
70 (80.5 )      
17 (19.5) 
32 (86.5 )       
5 (13.5%) 
Ever Diet                             
Never Diet 
1 (16.7)             
5 (83.3)              
84 (37%)      
143 (63%) 
32 (34.4%)      
61 (65.6%) 
13 (33.3%)       
26 (66.7%) 
Pre Hypertension                      
Hypertension                           
No Hypertension 
6 (100%)           
0 (0%)              
0 (0%) 
207 (91.2%)     
17 (7.5%)         
3 (1.3%)  
89 (95.7%)       
4 (4.3%)            
0 (0%)  
39 (100%)        
0 (0%)              
0 (0%)   
Pre Hypercholesterolemia      
Hypercholesterolemia                 
No Hypercholesterolemia 
4 (66.7%)          
2 (33.3%)          
0 (0%) 
160 (70.5%)     
52 (22.9%)         
15 (6.6%)  
66 (71%)        
27 (29%)            
0 (0%)  
24 (61.5%)        
11 (28.2%)              
4 (10.3%)   
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Pre Hyperglycemia           
Hyperglycemia                               
No Hyperglycemia 
6 (100%)           
0 (0%)              
0 (0%) 
220 (96.9%)     
6 (2.6%)           
1 (0.5%)  
90 (96.8%)       
3 (3.2%)            
0 (0%)  
39 (100%)        
0 (0%)              
0 (0%)   
Pre-levels of Elevated TG          
Elevated TG                                 
Not Elevated TG 
6 (100%)           
0 (0%)              
0 (0%) 
221 (97.3%)     
4 (1.8%)           
2 (0.9%)  
88 (94.6%)       
3 (3.2%)            
2 (2.2%)  
38 (97.4%)        
0 (0%)              
1 (2.6%)   
Pre-levels of  Reduced HDL 
+ 
     
Reduced HDL                        
Not Reduced HDL     
1(16.7%)           
3 (50%)              
2 (33.3%) 
13 (5.7%)       
88 (38.8%)           
126 (55.5%)  
24 (25.8%)       
48 (51.6%)            
21 (22.6%)  
6 (15.4%)        
12 (30.8%)              
21 (53.8%)   
Heart Problems (CHD)  +        
No Heart Problems 
0 (0%)              
6 (100%)            
5 (2.3%)        
217 (97.7%) 
0 (0%)              
92 (100%) 
7 (18.4%)       
31 (81.6%) 
Diabetes                                        
No Diabetes  
1 (16.7%)             
5 (83.3%)              
5 (2.3%)        
216 (97.7%) 
0 (0%)              
92 (100%) 
1 (2.6%)         
37 (97.4%) 
Mental Disorders                      
No Mental Disorders 
1 (16.7%)             
5 (83.3%)              
20 (8.9%)        
204 (91.1%) 
5 (5.6%)              
85 (94.4%) 
7 (17.95%)         
32 (82.05%) 
Other Health Problems           
No Other Health Problems 
1 (16.7%)             
5 (83.3%)              
22 (9.8%)        
202 (90.2%) 
6 (6.6%)              
85 (93.4%) 
0 (0%)              
39 (100%)         
Consumes Fastfood               
Does Not Consume Fastfood 
2 (33.3%)             
4 (66.7%)              
71 (31.3%)        
156 (68.7%) 
28 (30.1%)              
65 (69.9%) 
12 (30.8%)              
27 (69.2%)         
Frequent Weight Cyclers      
Occasional Weight Cyclers   
Not a Weight Cycler  
3 (50%)              
2 (33.3%)  
1(16.7%)            
96 (43.6%)       
118 (53.7%)           
6 (2.7%)  
34 (37.8%)       
49 (54.4%)            
7 (7.8%)  
16 (41.0%)        
23 (59%)              
0 (0%)   
Meets Carb. Guidelines               
Does Not Meet Carb. Guide.  
3 (50%)             
3 (50%)              
139 (61.2%)        
88 (38.8%) 
44 (47.3%)              
49 (52.7%) 
25 (64.1%)              
14 (35.9%)         
Meets Protein Guidelines               
Does Not Meet Protein Guide.  
5 (83.3%)             
1 (16.7%)              
218 (96%)        
9 (4%) 
87 (93.6%)              
6 (6.4%) 
36 (92.3%)              
3 (7.7%)         
Meets Fat Guidelines               
Does Not Meet Fat Guide.  
3 (50%)             
3 (50%)              
83 (35.6%)        
144 (63.4%) 
26(28%)              
67 (72%) 
11 (28.2%)              
28 (71.8%)         
Low Exercise Intensity       
Moderate Exercise Intensity 
High Exercise Intensity 
2(33.3%)           
2 (33.3%)          
2 (33.3%) 
101 (44.5%)       
66 (29.1%)           
60 (26.4%)  
41 (44.1%)       
30 (32.2%)            
22 (23.7%)  
12 (30.8%)        
16 (41.0%)              
11 (28.2%)   
ANOVA used for categorical variables; FISHER’s Exact Test used for continuous                                            
* Significant at p<0.05                                                                                                                                             
+ Significant at p<0.001 
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Figure 1: EOSS, METS & Framingham Risk Scales of Obese Individuals  
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Figure 2: EOSS Trajectories CARDIA study 
 
 
 
 
 
 
 
 
 
 
 
2 (Medium risk) 
 
 
 
1 (No risk) 
3 (High risk) 
 4 (Chronic Risk) 
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Table 3: Final Adjusted model of EOSS group membership  
Variable Group Adjusted OR     (95% CI) 
Sex (Male vs. Female) 
 
1             
2             
3 
 
 
 
0.64 (0.29-1.53)             
1.48 (0.97-2.24)+           
2.69 (1.64 – 4.41)* 
Race  (Black vs. White) 1                 
2              
3 
1.84 (0.85-3.96)              
0.53 (0.37-0.76)*            
1.83 (1.16-2.88)* 
Age 1              
2              
3 
1.01 (0.92-1.11)              
1.01 (0.97-1.06)               
1.08 (1.02-1.15)* 
Drinking (Moderate vs. Non Drinker)                           2 1.33 (0.77-2.29)+  
Currently On Diet  1              
2              
3 
0.71 (0.24-2.12)              
0.64 (0.39-1.07)+              
1.3 (0.71-2.37) 
Ever Diet  1              
2              
3 
1.12 (0.51-2.45)                 
0.57 (0.37-0.86)*            
1.57 (0.93-2.64) 
Follows protein consumption guidelines 1              
2              
3 
0.99 (0.36-2.74)              
2.08 (1.18-3.65)*           
2.79 (1.18-6.58)* 
Weight Cycling (occasional vs. non)               
 
Weight Cycling (frequent vs. non) 
1              
2              
3       
1              
2              
3 
0.65 (0.25-1.69)              
0.51 (0.29-0.9)*              
1.18 (0.58-2.4)                
0.35 (0.12-1.07)+               
0.25 (0.14-0.45)*           
0.76 (0.36-1.62) 
* OR significant at p < 0.05.                                                                                 
+ OR was significant at crude level before adjustments. Significance was lost 
after the variables were adjusted for each other.    
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3. Extended Discussion 
3.1 EOSS Trajectory Discussion 
 This study has demonstrated how obesity-related health risk develops and identified 
individuals who might be particularly at risk. Trajectory modelling was useful in the analysis of 
obese individuals in CARDIA and has shown to be a useful way of estimating obesity-related 
risk. Combined with EOSS, trajectory modelling has helped identify specific factors that were 
prevalent in the different observed trajectory groups.  
 Proc Traj analysis identified 4 distinct groups of individuals progressing through EOSS 
stages over time. It is assumed that every subject in each group follows the same trajectory.167 
Multiple different groups were examined before selecting the final model. Using previous 
research and guidelines set out by Daniel S. Nagin (2010),144 and after considering the BIC 
values, model complexity and clinical relevance, we selected a 4-group model as the most 
relevant to our EOSS and obesity examination. It showed the smallest available BIC number, 
was the most complex and had enough individuals in each group to perform meaningful 
subsequent analysis.  
 Generally, the stable “no-change” group is often the largest in the sample. However, due 
to the established global obesity trends and the knowledge that there is a constant age-related 
increase in body weight, we did not have a constant, “flat- line” trajectory group. That being said, 
our largest observed trajectory was the one that had the smallest probability of EOSS stage 
change.  
Figure 2 in the EOSS Manuscript shows the final 4-group model with EOSS stage 
probability over the mean age of the participants. Each line indicates the predicted trajectory 
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derived from the estimated regression coefficients. At baseline, obese individuals had a much 
poorer health profile, were on average about 40% heavier and were statistically different from all 
others on all continuous variables (p < 0.05). In addition to this, they were primarily black, 
female, were less likely be currently on a diet or have a history of dieting, had reduced HDL 
counts, higher occurrence of diabetes and pre-hypercholesterolemia, were more likely to be non-
drinkers and only have a high school education, as compared to the non-obese population. They 
also engaged less in physical activity and had a higher percentage of frequent weight cyclers 
(data not shown, p < 0.001). Multinomial logistic regression was used to predict specific group 
membership traits of the whole sample. Detailed univariate statistical results are presented in 
Appendix C, Table 6.   
Subjects in group 2, which represented about 57.6% of the population, had the smallest 
probability of moving to another EOSS stage. On the other hand, individuals in group 3 (24.2% 
of the population) had the highest likelihood of stage change, while group 4 individuals (13.9% 
of the population) were the highest at-risk group. Finally individuals in group 1, which 
represented only 4.3% (N=54) of the population, showed a constant decrease in overall EOSS 
risk. However, our final adjusted model was unable to identify any key factors to differentiate 
this group. Although the unadjusted model did show that individuals in this group were about 
66% less likely to be frequent weight cyclers, this effect was no longer significant after 
multivariable adjustment (Manuscript Appendix, Table 3).  
3.2 EOSS Stage Analysis 
 Proc Traj analysis was completed for the whole CARDIA baseline obese population 
(N=365). A censored normal model was used for the maximum likelihood estimates. Each 
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individual’s posterior group probability was significant at p<0.0001. Stage 0 individuals could be 
characterized as the ‘healthy but obese’ sample. They have a BMI greater than 30 kg/m2 but at 
the same time have none of the risk factors associated with higher EOSS stages, metabolic 
syndrome or any other health problems, diseases, or co-morbidities. Individuals in Stage 0 
remained a consistent minority (under < 5%) with only exam year 2 being the obvious exception 
(Appendix C, Figure 4). Because lipid information was not available, we cannot exclude bias to 
the null in these analyses, as the lack of lipid information in CARDIA may have underestimated 
EOSS stage in some groups.   
 To further understand the distribution (and accumulation) of risk factors over time, 
Appendix C, Figures 5-7 provides a breakdown of each EOSS stage at baseline, exam 5 (year 
10), and exam 7 (year 20). Please refer to Appendix A.3 for a detailed overview of each EOSS 
variable used in the modified definition.   
Reduced HDL seems to be a staple of EOSS stages 1 and 2 across all years of the study. 
Studies show that obesity is universally related to dyslipidemia which is mainly represented by a 
decrease in HDL-C levels.168 This is also true in the general population, where the wide and 
constantly increasing prevalence of low HDL-C has led to the development of many specific 
therapies to combat this threat in an effort to reduce or prevent heart disease and to some extent 
reduce obesity.197 As expected, high cholesterol is another condition that seems to be prevalent in 
EOSS stage 1 individuals across the study (App. B, figures 5-7). Obesity is a known risk factor 
for high cholesterol and both are subsequently associated with an increased risk of excess 
mortality.169 Compared with baseline, more individuals in year 20 stage 1 had pre-hypertension, 
high blood glucose levels and high TG levels. They also had a lower proportion of pre-HDL 
individuals and lower mental disorders (Appendix C, Table 3).     
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Beyond the lipid limitations noted above, we did not have enough detailed information in 
CARDIA to classify stage 3 mental-psychological criteria (e.g. major depression syndrome, 
severe anxiety/panic attacks or psychiatric conditions such as schizophrenia). Recent research 
into the issue of mental health and disability has revealed that about 26% of the adult American 
population suffer from a diagnosable mental disorder, while 6% of the populat ion suffers from a 
serious mental illness.170 What is more interesting, especially from an EOSS perspective, is that 
mental disorders are the leading cause of disability in the U.S. and Canada. 171 The co-morbid 
nature of most of these disorders greatly affects health and the overall burden of disease, 
especially in obese individuals. More extensive research is needed on this topic.  
3.3 Baseline sample generalizability 
Overall, the initial sample was much healthier than the average American at baseline. To 
this end, we compared some of the observed rates with those found in NHANES III (1989-1994) 
dataset. This dataset was chosen because it was the closest (time-wise) large-scale survey that 
was easily accessible. The final CARDIA sample had 0 individuals with cancer (vs 4% reported 
in NHANES).172 Additionally, CARDIA participants were much less likely to have hypertension 
(1.6% vs. 27%), high cholesterol (5% vs. 16%) and diabetes (0.06% vs. 43%), but be more likely 
to weight cycle (73% vs. 27%) and to be more active than average (68% vs. 30%). There was 
little to no difference in drinking (28% vs. 25%) and smoking habits (25% vs. 25% current, 13% 
vs. 25% former). Compared to other national samples of the time, smoking was less prevalent in 
the CARDIA sample.134 The metabolic syndrome (MetS) prevalence in NHANES was about 
6.7% amongst 20-29 year olds,173 as compared to 0.05% in CARDIA, further highlighting that 
the trajectory results depict a transition (and development of health risk) from a “healthy” cohort. 
Please see Appendix A.2 for supplemental baseline vs. last follow-up year (Year 20) comparison.   
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3.4 Comparison to similar literature  
 This is the first study looking at EOSS-related trajectory modelling analysis. There have 
only been three EOSS studies to date that address weight loss, bariatric surgery and mortality 
risk. The exploratory nature of this study, combined with CARDIA’s initial selection protocols 
and EOSS specifics, make it difficult to compare it to other literature or to generalize the 
findings. We can however, compare the general statistical methodology and the obesity related 
results. For instance, studies looking at BMI and weight trajectories have successfully used 4-
group models to identify meaningful trajectories of childhood obesity. 174 Another study looking 
at leisure time physical activity in a 22-year longitudinal study has also used a 4-group model to 
link social factors with patterns of physical activity. 175 Similar in design to our study, others have 
been able to use Proc Traj in tandem with multivariable logistic regression to distinguish at-risk 
children, using pre- and early post-natal risk factors.176 In general, most studies dealing with any 
type of obesity-related trajectory tend to select either 3-or 4-group models.177 178 179 Although 
some studies have selected a greater number of trajectories, this tends to occur only when there is 
a clear outcome (i.e. mortality) or a select number of specific variables (i.e. insulin resistance).180 
Further, our study confirms that individuals develop (and experience) obesity in many different 
ways, as a major finding of this study was the large variation in obesity trajectories. Additionally, 
this study presented a complex model, incorporating many factors not previously used together 
to study obesity.  
3.5 BMI Trajectory Example 
 It is not clear whether EOSS patterns are different from general weight-gain patterns in 
the CARDIA study. Therefore we conducted a similar 4-group trajectory modelling analysis of 
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categorical BMI trajectories (Appendix C, Figure 8). Participants in the largest group (group 1), 
had the lowest risk of increasing their BMI over the course of the study. Individuals in groups 2 
and 3 were more likely to gain weight (i.e. increase in BMI category), with trajectory 3 being the 
highest-risk group. Individuals who were obese at baseline (group 4) stayed obese, and their 
overall trajectory was very similar to that of group 1. More in-depth results can be found in 
Appendix A.4.  
Overall, it seems that being white, having a history of smoking (whether current or 
former), having at least a college-level education and moderate-to-high exercise level was found 
to be protective of BMI increase. Low BMI individuals were more likely to maintain their weight 
if they did a lot of high intensity exercises, did not diet or weight cycle, did not consume fast 
food, and attained a higher level of education. The observed BMI trends were similar to the ones 
identified in the EOSS study. While the BMI categorical testing identified physical activity and 
education as important factors in the development of obesity, protein guideline adherence was 
not significantly associated with group membership (Appendix C, Table 7). Furthermore, the 
identified model had a lower BIC value and a poorer overall model fit, suggesting no distinct (or 
dominant) trajectories. A subsequent continuous BMI trajectory model was examined, but again, 
the model fit was inferior to both categorical BMI and EOSS trajectory analyses (Appendix C, 
Figure 9).    
3.6 Study Limitations  
 As with any secondary analysis of this type, limitations with available variables, EOSS 
definitions and trajectory analysis must be discussed. Because this study makes use of existing 
data, certain information or specific questions on functional limitations and psychological 
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impairment were unavailable, resulting in the use of a modified EOSS definition. Further, the 
equal weighting of all co-morbid conditions in EOSS are weighted equally. Finally, perhaps the 
main limitation of EOSS is that individuals that fail to meet the current anthropometric cut-offs 
for obesity would not be considered for the system. These considerations are necessary due to the 
fact that the health risk associated with obesity starts earlier in Asian (and some other) 
ethnicities.181 It is also important to note that mortality studies point out the fact that physical 
activity and other lifestyle factors can reduce the overall health risk and improve the health 
profile of an individual independent of BMI and that EOSS is able to successfully demonstrate 
this.182 183 Please refer to Appendix A.5 for an in-depth analysis of other EOSS, CARDIA and 
Trajectory-modelling limitations.  
3.7 Future Research Directions 
Trajectory modelling analysis is a useful tool for exploring weight-change patterns and 
other obesity-related health risks. It allowed us to look at time varying covariates and to study 
repeated measures over a prolonged period of time. Given the multifactorial nature of obesity, no 
single factor is responsible for its global rise. As a result, treatment is challenging, but commonly 
includes interventions targeting simple motivation, diets and exercise to more complex behaviour 
modification strategies, weight loss drugs, and in some cases, surgery. 184 The ability of Proc Traj 
to model multiple groups of the sample, was useful in identifying specific EOSS ‘trends’, and 
can be used in the future to do other health-related analysis. It is hoped that this research can help 
further establish EOSS as an effective, individualized obesity risk- identification tool and aid 
future research on this topic. 
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Future studies need to focus on creating a detailed EOSS-tailored dataset to better 
evaluate all obesity-related measures. Running a trajectory modelling analysis on a full-variable 
dataset would have most likely yielded a slightly different, but more representative result. It is 
unrealistic to get a dataset or conduct a clinical study simply for testing EOSS, but this could be 
done in a research setting by garnering existing chart data. In order to optimize the management 
of obesity-related health from a population perspective, further research is necessary to evaluate 
how each individual EOSS component (physical/functional, medical and mental) contributes to 
the overall health risk.         
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Appendix A: Additional Discussion Points   
A.1 Summary of Observed Baseline Trends 
 Despite the initial balanced selection of individuals by sex, age, race and education, there 
were nevertheless significant sex and race-based baseline differences for the whole sample 
(Appendix C, Table 1). Most of the sex-based differences are understandable (i.e. men are in 
heavier and taller than women) and are in fact expected due to differential guidelines (i.e. WC, 
TG differences). However the race-based differences and the fact that they were significant for 
all the measured continuous variables are interesting and somewhat unexpected. Consistent with 
previous literature, black women had a much higher BMI than white women;185 while it’s true 
that group-based differences may exist in the body composition of blacks and whites, it does not 
explain the observed major differences in caloric consumption and exercise intensity. 186 White 
individuals also consumed fewer calories and had overall higher exercise intensity levels. This 
finding, however, is very similar to another study that concluded that in order to reduce their 
bodyweight below that of the average American, black Americans would need to be more 
restrictive in their caloric intake and be even more physically active.187 It is important to note, 
however, that both caloric and exercise intensity differences were not significant in the obese-
only portion of the baseline sample (Appendix C, Table 2). In fact, outside of expected 
divergences in weight and BMI, the only significant differences were for HDL and TG levels. 
These findings are essentially identical to what was found in a recent MetS study, suggesting that 
blacks are less likely than whites to have either elevated triglyceride or low high-density 
lipoprotein levels.188 Once again, it seems like an ethnic-specific criteria may be necessary in 
order for better identification of high-risk black individuals. 
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Besides race and sex, significant differences were found for education (obese less likely 
to go to college), drinking habits (obese less likely to drink), diet patterns (obese were much less 
likely to be on a diet or to have ever dieted), hypercholesterolemia, reduced HDL, CHD, 
diabetes, weight cycling and exercise frequency (Appendix C, Table 4). Not surprisingly, obese 
individuals were much more likely to weight cycle, and to exercise less than the healthy weight / 
overweight sample. Unexpectedly however, obese individuals were less likely to have CHD. The 
reasons for this are not clear since obesity is known to substantially increase the risk of 
developing CHD.189 190  
Overall, the whole CARDIA population followed a standard pattern of growth over the 
20 years of the study. As age increased, so did the BMI, WC, SBP, glucose, and triglyceride 
levels (Appendix C, Table 5). This is not unexpected, as many studies show that BMI, WC and 
systolic blood pressure increases with age.191 Plasma glucose levels and triglyceride levels are 
also known to increase with age, with caloric-restriction being the most effective anti-aging 
therapy.192 193 194 Exercise levels varied, but on average have decreased by about 20% from 
baseline. Studies show that the overall frequency of exercising at least once a week and the 
likelihood of continuing established exercise habits decline with age. 195      
A.2 Baseline vs. Year 20 Comparison 
Overall, as expected, the number of obese individuals increased throughout the study 
years. The initial sample was much healthier than the average American population of the time 
with only about 10% of the sample being obese (Appendix C, Table 3). However, 20 years 
later, the obesity rates of the sample (29.6%) were much closer to the current American obesity 
statistics (35.7%)196. Prevalence of smoking, alcohol consumption and diet history remained 
relatively unchanged (data not shown). Fast food consumption rates varied throughout the years 
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but in general, they were lower than baseline and this reflects the observed age-related dieting 
tendencies in the general population.197 198 Appendix C, Figure 1 shows the variables that had 
the largest change between baseline and year 20. Of particular interest is the fact that while 
exercise levels have gone down almost 50%, the number of individuals currently on a diet 
increased four-fold. This raises the much-contested issue of whether exercise or diet is more 
important in individual weight management and global obesity control.  Individual factors, such 
as current conditions (i.e. heart problems, diabetes, physical injuries), all play a major role in any 
weight management solutions. Some studies suggest that increased energy intake combined with 
a reduction in physical activity are not the only reasons behind the obesity epidemic. 199 Others 
suggest that a weight loss diet is not enough, and that maintenance of that weight loss also 
requires regular exercise.200 Exercise studies emphasize the fact that physical activity has 
beneficial health effects irrespective of weight loss.201 Others, like the recently completed Look 
AHEAD trial, find that intensive efforts to lose weight by eating less and exercising more didn’t 
provide any more protection against heart disease in a diabetic population. 202 Most studies, 
however, advocate that a combination of weight loss and exercise provides greater improvement 
in physical function than either intervention alone. 203 204  
 An overall increase in the number of EOSS Stage 2 and Stage 3 individuals can be in part 
attributed to an overall increase in all other medical conditions and disorders. Cancer, diabetes, 
CHD, hypertension, hypercholesterolemia, hyperglycemia, and triglyceride levels all increased 
significantly by year 20 of the study (Appendix C, Figure 2). HDL levels also decreased, with 
more than 40% of the remaining sample not meeting the accepted HDL cut-offs (Appendix C, 
Table 3). However, the CARDIA sample is still much healthier than the average population. 
Appendix C, Figure 3 illustrates the comparison between the CARDIA sample and the general 
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US population on the above-mentioned health conditions and disorders. Data for the comparison 
was drawn from the Centres for Disease Control and Prevention (CDC)205 206, the American 
Diabetes Association207, and the American Cancer Society208. Most of the available data is fairly 
recent, published within the past 5 years. Only the data for individuals ages 40-59 or 45-54 was 
used in the comparison to ensure that they are similar to the available year 20 CARDIA sample 
that was on average 45 years old. Surprisingly CARDIA had a slightly higher cancer and CHD 
prevalence rate and a much higher lowered-HDL rate (Appendix C, Figure 3). The differences 
in cancer rates can be due to the fact that the available population rates are not age-group specific 
and might underestimate the cancer prevalence in the 40-50 year olds. It is speculated that this 
number would be higher in this age group due to an increased prevalence of breast cancers in 
women.209 The reasons behind the HDL and CHD differences are unclear. There are many 
reasons why individuals might have a lowered HDL including smoking, being overweight, lack 
of physical activity, poor dietary choices, genetics, medical conditions such as diabetes, and 
possibly some medications.210 211 The exact cause is difficult to pinpoint, what is known 
nonetheless is that low HDL cholesterol levels increase the risk of CHD. 212 213 This can at least 
partially explain our observed finding but unfortunately, the reasons behind these particular 
trends in our dataset remain uncertain.        
A.3 EOSS Variables Breakdown 
  Due to missing variables, a modified EOSS definition had to be used. This portion of the 
appendix will explain and give a detailed breakdown of each individual EOSS stage components. 
It is important to note, that due to multiple unavailable factors (terminal illnesses, cancer-specific 
outcomes, sever psychiatric-psychological conditions, etc.) we were unable to designate or 
examine EOSS stage 4. It is quite possible that there were, in fact, stage 4 individuals in this 
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dataset, but they were missed or excluded from the analysis. However the lack of severe disease 
information, combined with the terminal, end-stage criteria for Stage 4, could be an indication 
that there were no such cases in CARDIA or that they were possibly excluded from the survey 
by the chief investigators. The relatively low cancer frequency throughout the early stages of the 
study and the overall superior baseline health of the sample reduce the probability of possible 
palliative (stage 4) subjects.  
 Many variables used in the EOSS definition were combined in order to conserve power, 
and to avoid over-stratification. In particular this was done to CHD, cancer, mental disorders and 
the ‘other health problems/diseases’ variable. The initial CARDIA CHD examination question 
asked individuals whether they had any heart problem. The participants were not locked to 
choose specific options and rather reported all possible heart-related conditions. These included 
arrhythmias, congenital heart defects/disorders, heart failure, heart valve disease, heart attacks, 
various arterial diseases and CHD itself. All these conditions were combined under one CHD 
‘umbrella’ term. The nature and number of different conditions reported prevented their 
meaningful categorization and this was avoided altogether to ensure a reasonable sample size.  
Similarly cancer was a very diverse variable, with over 10 different reported cancer sub-
types. To preserve power and to avoid over-stratification, all cancers were combined into one 
variable. Because of the low prevalence of cancer (0% at baseline, 4.7% at year 20), the 
combined variable was kept for the analysis, ignoring cancer-specific differences and their 
epidemiology. This is an obvious limitation of our study, especially knowing that there are a 
multitude of different cancers, each with their own, often unique treatment options.214 
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 In addition, no distinction was made between the different mental, emotional, nervous 
and psychiatric disorders with all of the individual incidences combined into a ‘mental disorders’ 
variable. This was done because of the numerous response categories and the innate difficulty of 
ranking the severity of psychological disorders without knowing all the specifics (i.e. how it 
affects the individual, stage of condition, whether medications are helping, etc.). Deciding 
whether something like an anxiety disorder should be ranked higher (EOSS-stage wise) than a 
depressive disorder is difficult, ambiguous and error-prone. The Diagnostic and Statistical 
Manual of Mental Disorders (DSM) is the best available tool used to diagnose and classify 
mental and psychiatric disorders.215 However, it does not attempt to rank the disorders in any 
way. Each disorder has varying levels of severity and attempting to rank them is very difficult. 
Standardizing such as classification system would be close to impossible.  
We used the combined mental disorder variable, together with the ‘other health 
problems/diseases’ variable for the psychological components of EOSS. The reasons for this are 
two-fold. Many of the other health problems inadvertently included some psychological 
conditions (panic attacks). It is possible that the participants did not want to report these 
conditions as mental health issues, and as a result considered them to be part of the ‘other 
problems’ question. Second, the known co-morbid nature of some psychological disorders can 
help to possibly identify more individuals (improve sensitivity) who were missed by the mental 
disorders question.216 217 
A.3.1 Physical activity calculations 
 Physical activity was calculated by the CARDIA researchers by adding a weighted sum 
of the number of months for each activity and the number of hours per week. The intensity level 
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of each activity was represented as the number of kilocalories believed to be spent in one minute 
of activity by an average male (70 kg). Running and vigorous racket sports, and other team 
sports (skiing, football, basketball, etc)  were considered to be the most intense, followed by 
biking, swimming, vigorous exercise/dancing, shoveling/weight- lifting, carrying heavy 
objects/digging, vigorous team sports, non-strenuous sports (softball, volleyball, ping-pong), 
home exercise, gardening, home maintenance, and finally bowling/golf as the least intensive. 
Moderate intensity sports are combined with the high intensity sport to produce the Total 
intensity variable that was used for this analysis. Individuals were categorized into 3 groups, 
taking into account sex-based physical activity differences. Information on physical/functional 
limitations was only available starting from exam 4 (year 7). Individuals were asked whether or 
not they had medical problems that affect their exercise ability (d iscomfort, pain, breathing 
problems, etc.). Those that reported problems were subsequently asked to rate (on 5 point scale) 
how much these medical problems affected or interfered with their exercise ability. Using these 2 
variables together, we have created the problems exercising variable that served as our 
classification for the functional limitations portion of EOSS.   
 A.3.2 Smoking and Alcohol calculations 
Smoking and drinking preferences were self-reported at each exam follow-up. 
Participants were asked about their cigarette, cigar and pipe smoking practices, but these 
different preferences were not looked at separately and were instead combined into one smoking 
variable. Individuals were reported to be non-, former or current smokers. Similarly, individuals 
were designated as non-, moderate and heavy drinkers, based on their reported alcohol 
consumption practices. The CARDIA researchers created a formula to calculate alcohol 
consumption and it was as follows: total alcohol consumed = (#of beer drinks per week/7*14.2) 
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+ (#of wine drinks per week/7*21.3) + (#of liquor drinks per week/7*23.7). Drinks were then 
converted into millilitres of alcohol per day. Individuals that reported drinking less than 13.7 
ml/day were considered non-drinkers, those that drank between 13.7 – 41.1 ml were moderate 
drinkers and everyone else above 41.1 were designated heavy drinkers. These cut-offs were 
similar to what was used in other alcohol-research studies.218 219 Similar to what was done by 
Kuk et al. (2011), most of the metabolic variables used in EOSS were divided into 3 levels. 
Blood pressure (SBP and DBP), cholesterol, glucose, HDL and triglyceride levels in individuals 
were defined as being in the normal range, close to established cut-offs (i.e. pre-hypertension), 
and above the cut-offs (i.e. hypertension). These were the so-called obesity-related subclinical 
risk factors which serve as good predictors for overall obesity risk.       
A.4 Detailed BMI Trajectory Example Results 
 Appendix C, Figure 8 shows the results of a 4-group trajectory model of BMI 
categories. Unlike the EOSS results, the groups were more balanced, but at the same time 
showed fairly similar trajectories. Overall, there were 1387 individuals in group 1, 957 in group 
2, 722 in group 3, and 624 in group 4. These trajectories can be described as “No-risk minimal 
weight gain”, “Medium-risk moderate weight gain”, “High-risk high weight gain” and “Chronic-
risk stable weight” for groups 1, 2, 3 and 4 respectively. Unlike what was observed with EOSS 
trajectories, BMI category trajectories used the whole population and the group percentages were 
identical to the actual observed group membership rates.  
Compared to group 4, group 1 (“no-risk”) individuals were more likely to be slightly 
older (OR=1.06 95% CI =1.03-1.10), have at least a college education (OR=2.39 95% CI=1.43-
4.00) be either current (OR=1.58 95% CI=1.21-2.08) or former (OR=1.94 95% CI=1.32-2.84) 
smokers and exercise at higher intensity (OR=1.64 95% CI=1.23-2.20). They were also much 
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less likely to be male (OR=0.48 95% CI=0.37-0.63), black (OR=0.16 95% CI=0.12-0.21), be on 
a diet (OR=0.34 95% CI=0.22-0.51) or have ever dieted before (OR=0.17 95% CI=0.13-0.23), 
eat fast food (OR=0.62 95% CI=0.48-0.80) or have a history of any type of weight cycling 
(Appendix C, Table 7). Group 2 individuals had normal level BMI at baseline and in general, 
became overweight by the last examination. Compared to the obese, group 4 trajectory, group 2 
individuals were more likely to be older (OR=1.08 95% CI =1.04-1.12), have at least a college 
education (OR=2.08 95% CI=1.22-3.54), be former smokers (OR=1.6 95% CI=1.09-2.35), and 
exercise at higher intensity (OR=1.39 95% CI=1.04-1.86). Similarly to group 1, they were 70% 
less likely to black, 51% less likely to be on a diet, 73% less likely to have ever dieted before, 
and also 70% less likely to have ever weight cycled in their lives (Table 7).  
 All of these patterns were not unexpected and have been observed in other literature. For 
example, many studies show that smoking is inversely associated with weight gain.220 Nicotine 
increases energy expenditure and could also reduce appetite, further contributing to the observed 
body weight differences.221 But it has also been found that smokers who quit tend to gain 
weight.240 222 One group of researchers has even suggested that the recently imposed smoking 
bans (i.e. in public places), have contributed to rising obesity rates in the U.S.223 Others suggest 
that rising rates of sedentary behavior, combined with smoking habits contribute to the observed 
weight gain in smokers.224 Many studies also show the negative effects of bad diets and 
systematic yo-yo-diets (aka weight cycling).225 226 227 This would explain why the individuals 
that did not diet or weight cycle were much more likely to not gain weight, and thus remain in 
the lower risk groups. There are many known beneficial effects of various forms of exercise and 
these will not be discussed in detail in this paper. Suffice to say, many studies show that exercise 
is associated with weight loss, weight control and overall general health,228 229 greater weight 
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loss following bariatric surgery,230 reductions in risk for all-cause and cardiovascular mortality231 
232 and can even help reduce the risk of various neurodegenerative diseases.233  
A.5 Trajectory-based and other limitations  
A.5.1 CARDIA limitations 
 Because this study makes use of existing data, no information was available on functional 
impairments or disabilities in the presence of specific health conditions or diseases. It is therefore 
unclear to what extent the disease affects his daily life. This prevented the creation of an EOSS 
stage 4 category, which in turn may have underestimated EOSS stage and subsequent obesity-
related risks.  
Also, while there was some information available on the various psychological and 
psychosocial problems, it was not inclusive enough to provide reliable evidence for the 
psychopathology portion of the EOSS definition. The only applicable information was drawn 
from the component of the medical history questionnaire that dealt with nervous, emotional, or 
mental disorders. This component was a simple yes/no question, followed by a few follow-up 
questions. The options for the condition were ‘under control’, ‘still have’ and ‘cured or gone’. 
Similar to what was discussed in the heart disease example above, it is not clear how an 
individual with an emotional disorder (i.e. GAD – general anxiety disorder) who indicates that 
they “still have” the condition was actually affected by the condition. In addition to this it is very 
difficult to understand how specific psychological conditions relate to obesity. For example, an 
individual suffering from a major depression disorder (MDD) can have periods of agitation, low 
self-esteem and loss of interest or pleasure in activities that were once enjoyed234 but this does 
not mean that he does not participate in physical activity or that he became obese because of 
these periodic depression bouts.  
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A.5.2 EOSS Limitations 
 Some of the EOSS criteria or treatment options are very flexible and can be subject to 
opinion bias or misinterpretation. Clinical definitions, management steps or treatment protocols 
for conditions such as hyperglycemia may change over time or might not be constant across 
different ethnicities and countries. Independent clinicians/researchers might consider one 
condition or disease more prevalent in their region and would thus attribute more importance to 
this condition. This could be an especially serious problem with certain mental disorders, where 
due to cultural standards or beliefs, a diagnostic bias could result in a misdiagnosis or 
underestimate the overall health risk. For example, a clinician utilizing EOSS in US will attribute 
a higher weight to diabetes, especially when diagnosing Hispanic/Latino and non-Hispanic black 
patients, two populations known to have a higher prevalence of this disease. 235 It is important to 
note, however, that while these obesity-related conditions are important, their exact effect on the 
various EOSS stages is questionable and that ultimately, the health risk will not be predicted 
equally by each different condition. However, our analysis was able to demonstrate that some 
conditions are much more likely to be present in a particular EOSS stage, with for example, 
CHD being the most frequently reported stage 3 condition, and reduced HDL being present in 
the vast majority of stage 2 individuals.  
The risk assessment and subsequent disease prognosis can be subjective in the sense that 
an individual that has lived with a chronic disease for an extended per iod of their lives and had 
therefore, structured their lives accordingly, might in fact, suffer less from the debilitating effects 
and/or physical limitations of that particular condition (i.e. arrhythmia). On the other hand, a 
recently diagnosed individual with the same condition might indicate that this circumstance is 
preventing them from doing everyday tasks and that they are subsequently under severe 
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psychological stress. The impact of their condition might also change over time, as in the case 
where a patient learns to cope and live with his or her condition (managing their symptoms, 
establishing new patterns of daily life, etc.), thus reducing the overall negative impact on their 
everyday lives.236 What this implies is that EOSS stage severity might not be very comparable 
between different individuals. Two individuals might have the same physical limitation but one 
reports suffering minor limitations and is categorized as stage 1, while the other feels that he is 
much worse off and is categorized stage 2. There is also a fine line between what could be 
considered a ‘moderate’ versus ‘severe’ quality of life limitation.  
Psychological impact and functional performance are also subject to self- report bias 
(differences in perception, social desirability, embarrassment etc); however, other classification 
systems and studies, such as the NHANES or social anxiety questionnaires have incorporated 
similar measures into their structure and it has worked well in clinical practice. 237 238 239 While it 
is clear that a stage 0 individual would have no psychopathology of any kind, it becomes difficult 
to rank and judge the various psychological issues for subsequent EOSS stages. This level of 
impairment is very challenging to evaluate and its subsequent assignment to a particular EOSS 
stage could pose a difficulty to the researcher. For example, an obese individual (BMI = 33) with 
schizophrenia (a significant psychopathology) who is otherwise relatively healthy would have 
class I, EOSS stage 2 or 3 obesity.  Would that individual actually require pharmacological or 
surgical weight loss interventions? Or would treating schizophrenia alone suffice? For this 
particular case, some evidence exists that patients with schizophrenia might be prone to 
obesity,240 while other evidence shows that certain medications might actually contribute to 
weight loss in schizophrenics with type II diabetes.241  
A.5.3 Trajectory Modelling Limitations 
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Given the relatively new nature of the trajectory modelling analysis and the experimental 
nature of its health-related application, it is important to consider some issues inherent with this 
type of statistical analysis. This paragraph will discuss some of the known issues associated with 
it, and identify additional issues that we discovered while working on this paper. It is often 
difficult to choose the number of groups for the final model. Some use a specific fit statistic such 
as the Bayesian Information Criterion to make their decision. Others use the clinical validity of 
the observed model. Alternatively, it is suggested that a combination of formal statistical criteria 
as well the usefulness and validity of the model as it relates to the research question should be 
used to justify the model choice.144 These are all fairly vague suggestions that are difficult to 
standardize because of the fact that group-based trajectory models are fairly new in clinical 
research. Additionally, the groups created using Proc Traj are not valid, ‘real’ groups. Rather 
they are representations of approximate patterns of change over given time. Thus they can 
potentially change over time or with additional follow-ups. However, same-group individuals are 
assumed to follow an identical pattern of change, meaning that intra-group variability cannot be 
measured.189 Furthermore, a large sample size is required to be able to successfully identify 
specific trends, especially in complex, multiple-group models.       
Finally there are a couple general limitations in this thesis. First of all, this report did not 
evaluate the theory or the effectiveness of trajectory modelling as a concept. The detailed 
statistical models and theory were not reviewed. The main focus was on examining EOSS as an 
effective obesity risk evaluation & prediction tool in a longitudinal setting. In this regard, 
trajectory modelling analysis was used to establish patterns of EOSS stage shift and the 
subsequent identification of associated risk factors. As mentioned before, the oversimplification 
and combination of certain variables was a major limitation in this paper. The inability to look at 
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obesity-specific cancers or other obesity-related health problems reduced the overall 
effectiveness of our analysis. The lack of any high-quality physical- functional variables could 
have underestimated EOSS stage severity and forced us to use a modified EOSS definition, 
different from the one designed by the original creators. Unfortunately, this limitation prevented 
us from evaluating the contributions of each individual EOSS component to the overall obesity-
related health risk. We were also unfortunately unable to include built environment interactions, 
socio-economic status, and other individual variables (i.e. familial history) which are known to 
influence obesity relationships and could have been the reasons for our observed gender and 
ethnicity differences.242     
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Appendix B: Stage Descriptions and other Guidelines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
63 
 
Table 1: EOSS stage descriptions
148 
EOSS 
Stage 
Medical 
Limitations1 
Mental 
(Psychological) 
Limitations1 
Functional 
Limitations1 
Management Steps 
Stage 0* None None None Identify factors contributing 
to increased weight. 
Counsel to prevent further 
weight gain (healthy eating 
and increased physical 
activity). 
Stage 1 Obesity-related 
SUBCLINICAL risk 
factors (borderline 
hypertension, impaired 
fasting glucose, etc) 
Mild impairments 
to well-being, o r 
mild psychological 
symptoms (Quality 
of life is not 
affected) 
Mild physical 
symptoms. No 
medical treatment is 
required. (dyspnea, 
aches, fatigue on 
exertion) 
Investigate other (non 
weight-related) risk factors.  
More intense lifestyle 
interventions combined with 
monitoring of risk factors 
and health status. 
Stage 2 Established obesity-
related comorbidit ies 
(Type 2 Diabetes, Sleep 
Apnea, Osteoarthritis, 
HTN, etc.). Medical 
Intervention is required.  
Moderate 
psychological 
symptoms 
(depression, eating 
disorder, anxiety 
disorder) 
Moderate functional 
limitat ions. Quality 
of life is beginning to 
be impacted.  
Start obesity treatments 
(consider all behavioral, 
pharmacological and 
surgical options). Close 
monitoring and managing 
comorbid ities.  
Stage 3 Significant obesity-
related end-organ 
damage (myocard ial 
infarct ion, heart failure, 
diabetic complications, 
etc).  
Significant obesity-
related 
psychological 
symptoms (major 
depression, suicide 
ideation) 
Significant functional 
limitat ions (unable to 
work, reduced 
activity). Quality of 
life is significantly 
affected.  
Intensified obesity 
treatment. Aggressive 
management of 
comorbid ities.   
Stage 4 End-stage life-
threatening obesity-
related comorbidit ies 
Severe 
psychological 
symptoms 
Severe functional 
limitat ions. Most 
likely palliat ive care 
required.  
Aggressive obesity 
management (as deemed 
feasible). Palliative 
measures including pain 
management, occupational 
therapy, psych. support.  
* Also no sign of other obesity-related risk factors 
1
 Patient has to display 1 of either of the 3 categories to be classified to the relevant EOSS stage. 
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Table 2: Metabolic Syndrome and Framingham Risk Score Guidelines 
US National Cholesterol Education Program 
Adult Treatment Panel III Updated (2004) 
Metabolic Syndrome  Guidelines 
Canadian Cardiovascular Society  Framingham 
Heart Study 10-year Coronary Heart Disease  
Development Guidelines (2009) 
Risk Factor Guidelines Risk Factor Guidelines 
Elevated Waist 
Circumference  
Men > 40 inches (102 cm) 
Women > 35 inches (88 
cm) 
Age Older individuals at higher 
risk 
Elevated 
Triglycerides 
= or > 150 mg/dL (1.7 
mmol/L)  
Sex Males at higher risk 
Reduced HDL 
cholesterol 
Men < 40 mg/dL (1.03 
mmol/L) 
Women < 50 mg/dL (1.29 
mmol/L) 
Smoking Higher risk for Smokers 
High Blood 
Pressure (HBP) 
= or > 130/85 mm Hg or 
use of HBP Medication 
Total cholesterol  <200 mg/dL ‘Desirable’  
200-239 mg/dL 
‘Borderline-high’ 
240 mg/dL or > ‘High’ 
Elevated Fasting 
Glucose 
(Hyperglycemia) 
= or > 100 mg/dL (5.6 
mmol/L) or use of 
hyperglycemic medication 
HDL cholesterol < 40 mg/dL ‘Major risk’ 
40 to 59 mg/dL ‘Normal’  
60 mg/dL ‘Protective’ 
  Systolic Blood 
Pressure 
< 130 (mm Hg) ‘No risk’  
130-159 (mm Hg) ‘risk’  
>160 (mm Hg) ‘high risk’  
  Diabetes Higher risk for Diabetics 
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proc traj data=box.trialdata outplot=plot outstat=OS out=out; 
VAR EOSS_STAGE1-EOSS_STAGE7; INDEP age1-age7; 
MODEL cnorm; 
MAX 5; 
NGROUPS 4; 
ORDER 2 3 3 3; 
ID PID; 
run; 
%trajplot (plot, os, 'Title', 'Subtitle', 'probability of EOSS Stage', 
'age'); 
Where VAR is the variable of interest. ID is the subjects in the population. 
INDEP defines the time variable over which the outcome is modeled.  
MODEL identifies the type of model and NGROUPS is the number of groups.  
ORDER assigns the order of each equation (i.e. linear, quadratic, etc.)  
%TRAJPLOT is a macro statement that is responsible for a graphical output  
Figure 2: Proc Traj EOSS Example 
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Appendix C: Detailed Analysis Figures                                      
Table 1: T-tests of Baseline Differences between Sex & Race (N=3690) 
 Male vs. Female Black vs. White 
Variable Name Male 
Mean 
(SD) 
Female 
Mean 
(SD) 
Signif.  Black 
Mean (SD) 
White 
Mean (SD) 
Signif.  
Height (cm) 177.6 
(6.6) 
164.3 
(6.4) 
P <.0001 169.4 (9.3) 171.2 (9.3) P <.0001 
Weight (lbs) 168.1 
(27.2) 
144.4 
(32.5) 
P <.0001 159 (35.5) 151.3 
(28.8) 
P <.0001 
WC (cm) 81.21 
(8.2) 
73.74 
(10.6) 
P <.0001 77.9 (11.1) 76.26 (9.4) P <.0001 
 BMI (Kg/M
2
) 24.18 
(3.4) 
24.31 
(5.3) 
NS 25.17 (5.3) 23.37 (3.5) P <.0001 
SBP (mm Hg) 114.7 
(10.4) 
106.4 
(9.6) 
P <.0001 111.4 
(10.9) 
108.9 
(10.6) 
P <.0001 
DBP (mm Hg) 70.66 
(9.9) 
66.72 
(8.8) 
P <.0001 68.83 
(10.0) 
68.15 (9.0) P <.05 
Calories (KCal) 3570 
(1909.5) 
2322.4 
(1147.2) 
P <.0001 3127.1 
(1970.3) 
2648.5 
(1247.1) 
P <.0001 
Glucose (mg/dL)  83.98 
(10.04) 
80.24 
(12.2) 
P <.0001 81.33 
(12.7) 
82.46 
(10.1) 
P <.05 
TG (mg/dL) 75.36 
(43.6) 
64.61 
(32.9) 
P <.0001 64.79 
(31.8) 
73.83 
(43.3) 
P <.0001 
HDL (mg/dL) 50.62 
(12.5) 
55.98 
(12.6) 
P <.0001 54.73 
(12.9) 
54.48 
(12.7) 
P <.0001 
Intensity (METs Units) 517.4 
(322.5) 
345.4 
(254.5) 
P <.0001 382.3 
(310.5) 
460.6 
(283.3) 
P <.0001 
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Table 2: OBESE Baseline Differences between Sex & Race (N=365) 
 Male (N=102) vs. Female (N=263) Black (N=270) vs. White (N=95) 
Variable 
Name 
Male  
Mean (SD) 
Female 
Mean (SD) 
Signif.  Black Mean 
(SD) 
White Mean 
(SD) 
Signif.  
Height (cm) 178.5 (6.7) 163.2 (6.2) P <.0001 166.9 (9.2) 169.0 (9.6) NS 
Weight (lbs) 228.7 (23.6) 205.8 (30.7) P <.0001 214.6 (32.9) 205.4 (22.1) P <.05 
WC (cm) 99.34 (6.2) 94.4 (10.2) P <.0001 95.49 (10.3) 93.84 (7.1) NS 
 BMI (Kg/M
2
) 32.6 (2.2) 35.2 (4.5) P <.0001 35.01 (4.5) 32.8 (2.3) P <.0001 
SBP (mm Hg) 118.4 (9.8) 111 (9.9) P <.0001 113.5 (10.6) 111.9 (9.9) NS 
DBP (mm 
Hg) 
71.7 (8.6) 70 (8.5) NS 70.31 (8.7) 70.84 (8.2) NS 
Calories 
(KCal) 
3552.6 
(1702.3) 
2311.9 
(1146.7) 
P <.0001 2678.7 
(1443.5) 
2601.6 
(1184.5) 
NS 
Glucose 
(mg/dL) 
85.1 (6.9) 83.5 (8.2) NS 83.68 (8.1) 84.58 (7.1) NS 
TG (mg/dL) 96.65 (45.9) 71.88 (32.5) P <.0001 74.69 (38.1) 90.49 (36.8) P <.001 
HDL (mg/dL) 44.09 (9.9) 48.33 (10.6) P <.001 48.13 (10.8) 44.37 (9.4) P <.05 
Intensity (Ex. 
Units) 
465.5 
(303.2) 
267.9 
(200.9) 
P <.0001 314.3 (257.5) 348.1 (226.2) NS 
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Table 3: Categorical Variable Distribution at each follow-up (N=3692) 
 Examination Year 
Exam 1 
(Base) 
Exam 2 
(Year2) 
Exam 3 
(Year 5) 
Exam 4 
(Year7) 
Exam 5 
(Year10) 
Exam 6 
(Year15) 
Exam 7      
(Year 20) 
Variables Total (%) Total (%) Total (%) Total (%) Total (%) Total (%) Total (%) 
Race        
Black 
White 
1798 
(48.7)  
1894 
(51.3) 
1782 
(48.5)  
1889 
(51.5) 
1676 
(47.7)  
1835 
(52.3) 
1676 
(47.8)  
1834 
(52.2) 
1709 
(48.5)  
1816 
(51.5) 
1550 
(47.1)  
1742 
(52.9) 
1382 
(45.7) 
1642 
(54.3) 
Sex        
Male 
Female 
1654 
(44.8) 
2038 
(55.2) 
1642 
(44.7) 
2029 
(55.3) 
1568 
(44.66) 
1943 
(55.34) 
1572 
(44.8) 
1938 
(55.2) 
1580 
(44.8) 
1945 
(55.2) 
1469 
(44.6) 
1823 
(55.4) 
1316 
(43.5) 
1708 
(56.5) 
Education        
No Highschool   
  Highschool 
College or 
Univ. 
Prof. or Masters 
and higher 
256 (7.1)  
2150 
(59.2)    
1224 
(33.7)                
0 
170 (4.9) 
1858 
(53.7) 
1434 
(41.4)                             
                 
0 
148 (4.3) 
1691 
(48.7) 
1262 
(36.4)
                 
367 (10.6) 
144 (4.2) 
1581 
(46.1) 
1273 
(37.1) 
               
433 (12.6) 
0 
1577 
(47.1) 
1290 
(28.5) 
              
485 (14.4) 
0 
1270 
(41.0) 
1278 
(41.3) 
               
549 (17.7) 
0 
1092 
(38.2) 
1205 
(42.1)                                    
562 (19.7) 
BMI category         
Underweight 
Normal 
Overweight  
 
Obese  
143 (3.9)  
2323 
(62.9) 
861 
(23.3) 
              
365 (9.9) 
108 (3.1) 
1999 
(56.8)   
929 (26.4) 
 
480 (13.7) 
66 (1.9) 
1789 
(51.2) 
1009 
(28.9) 
                      
629 (18.0) 
309 (8.37) 
1587 
(42.98) 
1051 
(28.5) 
                    
745 (20.2) 
272 (7.4) 
1431 
(38.8) 
1128 
(30.55) 
                  
861 
(23.25) 
439 (11.9) 
1091 
(29.5) 
1107 
(30.0) 
             
1055 
(28.6) 
684 (18.5) 
894 (24.2) 
1022 
(27.7) 
                     
1092 
(29.6) 
Drinking        
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No Drinking 
Moderate  
Heavy  
2655 
(72.2) 
788 
(21.4) 
236 (6.4) 
2555 
(73.0)    
728 (20.8) 
215 (6.2) 
2652 
(75.9)   
635 (18.2) 
206 (5.9) 
2608 
(74.8)   
651 (18.7) 
228 (6.5) 
2624 
(74.8)   
659 (18.8) 
224 (6.4) 
2477 
(75.4)   
607 (18.5) 
201 (6.1) 
2191 
(73.9)   
602 (20.3)  
174 (5.8) 
Smoking        
Non Smoker 
Former  
Current 
2159 
(58.9) 
482 
(13.1) 
1028 
(28.0) 
2059 
(58.5)   
493 (14.0)  
967 (27.5) 
2050 
(58.5)   
509 (14.5) 
944 
(26.95) 
2030 
(58.1)   
559 (16.0) 
905 (25.9) 
2054 
(58.5)   
586 (16.7) 
869 (24.8) 
1978 
(60.2)   
598 (18.2) 
709 (21.6) 
1861 
(62.1)    
585 (19.5) 
550 (18.4) 
On a Diet        
Yes 
 
No 
276 (8.4)  
           
3027 
(91.6) 
245 (18.2) 
            
1099 
(81.8) 
NA 235 (18.1) 
           
1066 
(81.9) 
280 (35.7) 
                  
504 (64.3) 
292 (32.5) 
              
605 (67. 5) 
313 (33.5) 
                  
623 (66.5) 
Ever Diet        
Yes 
   
No  
1328 
(36.0) 
2359 
(64.0) 
1359 
(38.7) 
2152 
(61.3) 
NA 1315 
(37.6) 
2186 
(62.4) 
785 (22.3) 
            
2730 
(77.7) 
898 (27.3) 
            
2390 
(72.7) 
940 (31.2) 
                     
2073 
(68.8) 
Hypertension        
Prehypertension 
Yes 
No 
147 (4.0) 
60 (1.6) 
3485 
(94.4) 
110 (3.0) 
52 (1.4) 
3530 
(95.6) 
108 (2.9) 
111 (3.0) 
3473 
(94.1) 
153 (4.1) 
111 (3.0) 
3428 
(92.9) 
201 (5.5) 
167 (4.5) 
3324 
(90.0) 
247 (6.7) 
324 (8.8) 
3121 
(84.5) 
284 (7.7) 
266 (7.2) 
3142 
(85.1) 
Hypercholestero
lemia 
       
Precholestrol.  
Yes 
No 
643 
(17.4) 
154(4.2)     
2895 
(78.4) 
NA 628 (17.0) 
156 (4.2) 
2908 
(78.8) 
641 (17.4) 
151 (4.1) 
2900 
(78.5) 
612 (16.6) 
169 (4.6) 
2911 
(78.8) 
786 (21.3) 
199 (5.4) 
2707 
(73.3) 
774 (21.0) 
188 (5.1) 
2730 
(73.9) 
Hyperglycemia        
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Prehyperglyce. 
Yes 
No 
62 (1.7) 
13 (0.3) 
3617 
(98.0) 
NA NA 326 (8.8) 
30 (0.8) 
3336 
(90.4) 
214 (5.8) 
50 (1.35) 
3428 
(92.85) 
193 (5.2) 
63 (1.7) 
3436 
(93.1) 
679 (18.4) 
139 (3.8) 
2874 
(77.8) 
Problems 
Exercising 
       
Mild  
Moderate 
Severe 
NA NA NA 159 (16.7) 
435 (45.7) 
357 (37.5) 
143 (15.4) 
390 (42.1) 
394 (42.5) 
84 (15.9) 
254 (47.9) 
192 (36.2) 
81 (15.8) 
218 (42.4) 
215 (41.8) 
Elevated TG        
Pre-levels 
Yes 
No 
91 (2.5) 
42 (1.1) 
3559 
(96.4) 
NA 129 (3.5) 
93 (2.5) 
3470 
(94.0) 
171 (4.6) 
129 (3.5) 
3392 
(91.9) 
213 (5.8) 
179 (4.9) 
3300 
(89.3) 
256 (6.9) 
239 (6.5) 
3197 
(86.6) 
282 (7.6) 
257 (7.0) 
3153 
(85.4) 
Reduced HDL        
Pre-levels 
Yes 
 
No 
1814 
(49.1) 
860 
(23.3)  
1018 
(27.6) 
NA 1534 
(41.5) 
1136 
(30.8) 
1022 
(27.7) 
1467 
(39.7) 
1300 
(35.2) 
925 (25.1) 
1392 
(37.7) 
1495 
(40.5) 
805 (21.8) 
1212 
(32.8) 
1659 
(44.9) 
821 (22.3) 
1153 
(31.2) 
1553 
(42.1)                               
986 (26.7) 
Cancer        
Yes 
No 
0 
3673 
(100) 
74 (2.1) 
3431 
(97.9) 
40 (1.1) 
3463 
(98.9) 
60 (1.7) 
3442 
(98.3) 
74 (3.8) 
1861 
(96.2) 
96 (2.9) 
3186 
(97.1) 
140 (4.65) 
2870 
(95.35) 
Heart 
Problems 
(CHD) 
       
Yes 
No 
217 (6.0) 
3432 
(94.0) 
237 (6.8) 
3242 
(93.2) 
294 (8.4) 
3193 
(91.6) 
354 (10.1) 
3138 
(89.9) 
372 (10.6) 
3124 
(89.4) 
369 (11.3) 
2886 
(88.7) 
320 (10.8) 
2649 
(89.2) 
Diabetes        
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Yes 
No 
22 (0.06) 
3637 
(99.4) 
31 (0.09) 
3466 
(99.1) 
53 (1.5) 
3443 
(98.5) 
103 (2.9) 
3395 
(97.1) 
128 (3.7) 
3383 
(96.3) 
161 (4.9) 
3107 
(95.1) 
203 (6.8) 
2797 
(93.2) 
Mental 
Disorders 
       
Yes  
No 
260 (7.1) 
3389 
(92.9) 
243 (7.0) 
3247 
(93.0) 
NA 159 (4.5) 
3336 
(95.5) 
202 (5.7) 
3311 
(94.3) 
241 (7.3) 
3037 
(92.7) 
183 (6.1) 
2802 
(93.9) 
Other Health 
Problems/ 
Diseases 
       
Yes  
No 
303 (8.3) 
3358 
(91.7) 
231 (6.6) 
3252 
(93.4) 
347 (9.9) 
3148 
(90.1) 
249 (7.1) 
3252 
(92.9) 
287 (8.2) 
3229 
(91.8) 
254 (7.8) 
3023 
(92.2) 
285 (9.5) 
2717 
(90.5) 
Fastfood 
consumption 
       
Yes 
No 
1079 
(29.2) 
2613 
(70.8) 
NA 647 (17.5) 
3045 
(82.5) 
935 (25.3) 
2757 
(74.7) 
914 (24.8) 
2778 
(75.2) 
741 (20.1) 
2951 
(79.9) 
852 (23.1) 
2840 
(76.9) 
Weight 
Cycling 
       
Frequent 
Occasional 
 
No 
732 
(20.0) 
1915 
(52.5)  
1005 
(27.5) 
NA NA NA NA NA NA 
Meeting 
Carbohydrate 
Guidelines 
       
Yes 
No 
2020 
(54.7) 
1672 
(45.3) 
NA NA NA NA NA NA 
Meeting Protein 
Guidelines 
       
Yes 
No 
3496 
(94.7) 
196 (5.3) 
NA NA NA NA NA NA 
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Meeting fat 
consumption 
guidelines 
       
Yes  
No 
1153 
(31.2) 
2539 
(68.8) 
NA NA NA NA NA NA 
Presence of 
Metabolic 
Syndrome 
       
Yes 
No 
2 (0.05) 
3690 
(99.95) 
NA 80 (2.2) 
3612 
(97.8) 
237 (6.4) 
3455 
(93.6) 
299 (8.1) 
3393 
(91.9) 
443 (12.0) 
3249 
(88.0) 
698 (18.9) 
2994 
(81.1) 
Exercise 
Frequency & 
Intensity 
       
Low 
Moderate 
High  
1187 
(32.1) 
1251 
(33.9) 
1254 
(34.0) 
1514 
(41.0) 
1199 
(32.5)   
979 (26.5) 
1596 
(43.2) 
1131 
(30.6)   
965 (26.2) 
1820 
(49.3) 
1067 
(28.9)   
805 (21.8) 
1846 
(50.0) 
1053 
(28.5)   
793 (21.5) 
1903 
(51.5)    
993 (26.9) 
796 (21.6) 
2056 
(55.7)    
904 (24.5) 
732 (19.8) 
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Table 4:  Obese vs. Not Obese baseline categorical comparison (N=3690) 
Variables Not Obese Obese X2 Value Significance 
Race:                     
                                       Black 
White 
             
 1526 (45.9) 
            1799 (54.1) 
               
 270 (74.0) 
             95 (26.0) 
103.8 P < 0.0001 
Sex: 
Male 
Female 
 
1552  (46.7) 
1773 (53.3) 
 
102 (27.9) 
263 (72.1) 
46.53 P < 0.0001 
Education:   
No Highschool 
Highschool 
College or Univ. 
 
224 (6.9)  
1915 (58.5) 
1132 (34.6) 
 
32 (9.0) 
234 (65.5) 
91 (25.5) 
12.64 
 
 
 
P < 0.01 
Drinking: 
No Drinking 
Moderate  
Heavy 
 
2365 (71.4) 
729 (22.0) 
218 (6.6) 
 
288 (78.9) 
59 (16.2) 
18 (4.9) 
9.2 
 
P < 0.05 
Smoking: 
Non Smoker 
Former  
Current 
 
1953 (59.1)  
443 (13.4) 
911 (27.5) 
 
204 (56.7) 
39 (10.8) 
117 (32.5) 
4.8 NS 
On a Diet: 
Yes 
No 
 
2743 (92.5) 
222 (7.5) 
 
282 (83.9) 
54 (16.1) 
29.02 P < 0.0001 
Ever Diet: 
Yes 
No 
 
2229 (67.1) 
1091 (32.9) 
 
130 (35.6) 
235 (64.4) 
141.85 P < 0.0001 
Has Hypertension: 
Prehypertension 
Yes 
No 
 
126 (3.8)  
57 (1.7) 
3142 (94.5) 
 
21 (5.8) 
3 (0.8) 
341 (93.4) 
4.84 NS 
Hypercholesterolemia: 
Pre 
Yes 
No 
 
551 (16.6) 
135 (4.0) 
2639 (79.4) 
 
92 (25.2) 
19 (5.2) 
254 (69.6) 
19.17 P < 0.0001 
Hyperglycemia: 
Pre 
Yes 
No 
 
53 (1.6)  
12 (0.4) 
3260 (98.0) 
 
9 (2.5) 
1 (0.3) 
355 (97.2) 
0.53 NS 
Elevated TG: 
Pre 
Yes 
No 
 
84 (2.5) 
37 (1.1) 
3204 (96.4) 
 
7 (1.9) 
5 (1.4) 
353 (96.7) 
0.004 NS 
Reduced HDL: 
Pre 
Yes 
No 
 
1662 (50.0) 
690 (20.8) 
973 (29.2) 
 
151 (41.4) 
170 (46.6) 
44 (12.0) 
134.4 P < 0.0001 
CHD: 
Yes 
No 
 
204 (6.2)   
3085 (93.8) 
 
12 (3.4) 
346 (96.6) 
4.7 P < 0.05 
74 
 
Diabetes: 
Yes 
No 
 
15 (0.5) 
3285 (99.5) 
 
7 (2.0) 
350 (98.0 
12.22 P < 0.0005 
Mental Disorder: 
Yes 
No 
 
227 (6.9)  
3062 (93.1) 
 
33 (9.2) 
326 (90.8) 
2.6 NS 
Other Health Prob lems:       
                                          Yes 
No 
 
273 (8.3)  
3026 (91.7) 
 
29 (8.0) 
331 (92.0) 
0.021 NS 
Fast Food Consumption: 
Yes 
No 
 
966 (29.0)  
2359 (71.0) 
 
113 (31.0) 
252 (69.0) 
0.6 NS 
Weight Cycling  
Frequent 
Occasional 
No 
 
582 (17.7) 
1722 (52.3) 
991 (30.0) 
 
149 (42.0) 
192 (54.0) 
14 (4.0) 
174.24 P < 0.0001 
Meeting Carbohydrate 
Guidelines 
Yes 
No 
 
 
1808 (54.4)  
1517 (45.6) 
 
 
211 (57.8) 
154 (42.2) 
1.56 NS 
Meeting Protein Guidelines 
Yes 
No 
 
3148 (94.8)  
177 (5.2) 
 
346 (94.8) 
19 (5.2) 
0.009 NS 
Meeting fat consumption 
guidelines 
Yes 
No 
 
 
1029 (31.0)  
2296 (69.0) 
 
 
123 (33.7) 
242 (66.3) 
1.16 NS 
Presence of Metabolic 
Syndrome 
Yes 
No 
 
 
1 (0.03) 
3326 (99.97) 
 
 
1 (0.3) 
364 (99.7) 
0.51 NS 
Exercise Frequency & 
Intensity 
Low 
Moderate 
High  
 
 
1031 (31.0) 
1136 (34.2) 
1158 (34.8) 
 
 
156 (42.7) 
114 (31.2) 
95 (26.1) 
22.4 P < 0.0001 
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Table 5: Continuous Variable Distribution at each follow-up (N=3690) 
 Examination Year 
Exam 1 
(Base) 
Exam 2 
(Year2) 
Exam 3 
(Year 5) 
Exam 4 
(Year7) 
Exam 5 
(Year10) 
Exam 6 
(Year15) 
Exam 7      
(Year 20) 
Variables Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean 
(SD) 
Mean (SD) Mean (SD) 
Age (years) 24.87 
(3.6) 
26.95 (3.6) 29.97 (3.6) 31.98 (3.6) 34.94 (3.6) 40.1 (3.63) 45.1 (3.56) 
Height (cm) 170. 3 
(9.3) 
170.1 (9.3)  170.4 (9.3) 170.9 (9.2) 170.8 (9.2) 170.96 (9.2) 170.7 (9.25) 
Weight (lbs) 155.0 
(32.5) 
159.4 
(34.6) 
165.7 
(37.5) 
170.7 
(39.1)  
175.1 
(41.2) 
183.1 (43.3) 186.7 (44.0) 
WC (cm) 77.1 
(10.3) 
79.3 (11.1) 81.3 (11.8) 83.4 (13.5)  85.2 (13.4) 88.7 (13.9) 91.1 (14.5) 
BMI (kg/m
2
) 24.2 (4.5) 25.0 (4.9) 25.9 (5.4) 26.5 (5.7) 27.2 (6.0) 28.4 (6.3) 29.1 (6.4) 
SBP (mmHg) 110.1 
(10.8) 
107.6 
(10.7) 
107.6 
(11.8) 
108.4 
(12.1) 
109.8 
(12.6) 
112.8 (14.6) 116.4 (15.0) 
DBP (mmHg) 68.5 (9.5) 67.4 (9.5) 69.2 (10.3) 69.1 (10.2) 72.3 (10.1) 74.4 (11.5) 72.9 (11.4) 
Calories 
(KCAL) 
2881.5 
(1656.7) 
2468.8 
(1765.9) 
NA 3003.4 
(1893.5) 
NA NA NA 
Glucose 
(mg/dl) 
81.9 
(11.4) 
NA NA 89.1 (14.5) 87.3 (15.4) 85.9 (17.9) 97.0 (23.4) 
Trig lycerides 
(mg/dl) 
69.4 
(38.4) 
NA 76.5 (57.8) 82.7 (62.5) 88.5 (62.2) 101.7 (78.9) 107.3 (77.1) 
Total HDL 
Cholesterol 
(mg/dl) 
53.6 
(12.8) 
NA 53.7 (14.0) 52.3 (14.1) 50.5 (13.9) 50.9 (14.5) 54.5 (16.6) 
Total PA 
Intensity score 
(exercise 
units) 
422.5 
(299.4) 
382.2 
(284.5) 
380.0 
(293.9) 
340.4 
(274.8) 
330.9 
(275.6) 
347.4 
(283.7) 
338.5 
(277.5) 
Heavy 
Intensity Only 
(exercise 
units) 
297.6 
(232.1) 
252.0 
(223.5) 
250.4 
(230.0) 
218.4 
(216.0)  
209.2 
(214.8) 
213.1 
(220.2) 
203.8 
(211.2) 
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Table 6: Logistic Regression Univariate Results  
Variable Group** Unadjusted OR (95% CI) 
Sex (Male vs. Female) 1            
2            
3 
0.67 (0.3-1.52)                
2.16 (1.47-3.2)*              
2.33 (1.48 – 3.67)* 
Race  (Black vs. White) 1            
2            
3 
2.09 (0.998-4.38)            
0.63 (0.44-0.88)*             
1.58 (1.03-2.44)* 
Age  1              
2             
3 
0.98 (0.89-1.07)              
1.00 (0.96-1.05)              
1.06 (1.00-1.13)* 
Education (HighSchool (HS) vs. No HS)                 
                                                                  
Education (College + vs. No HS) 
1            
2            
3            
1            
2            
3 
2.03 (0.42-9.76)              
1.07 (0.54-2.09)              
1.29 (0.56-3.01)              
1.20 (0.23-6.21)              
1.02 (0.51-2.05)              
0.91 (0.38-2.19) 
Drinking (Moderate vs. Non-Drinker) 
                                                                  
Drinking (Heavy vs. Non-Drinker)  
1            
2            
3            
1            
2            
3 
1.85 (0.78-4.38)              
1.93 (1.16-3.19)*            
1.68 (0.93-3.03)              
0.83 (0.17-4.10)              
1.21 (0.58-2.52)              
1.04 (0.42-2.60) 
Smoking (Former vs. Non-Smoker)                                                                                                     
                                                                          
Smoking (Current vs. Non-smoker) 
1
2             
3            
1            
2            
3 
0.15 (0.02-1.16)
1.18 (0.70-1.94)              
0.66 (0.34-1.29)              
1.24 (0.59-2.63)                
1.35 (0.89-2.04)              
1.07 (0.65-1.77) 
Currently On Diet 1              
2              
3 
0.62 (0.22-1.72)              
0.39 (0.25-0.63)*            
1.19 (0.68-2.07) 
Ever Diet 1              
2              
3 
0.80 (0.41-1.57)              
0.39 (0.28-0.56)*             
1.04 (0.68-1.59) 
Follows carbohydrate consumption guidelines 1              
2              
3 
0.90 (0.46-1.76)              
0.99 (0.71-1.40)              
0.87 (0.57-1.33) 
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Follows protein consumption guidelines 1            
2            
3 
0.87 (0.32-2.37)              
2.43 (1.41-4.21)*            
3.28 (1.41-7.64) * 
Follows fat consumption guidelines 1            
2            
3 
1.55 (0.75-3.22)               
1.48 (0.995-2.21)            
1.35 (0.84-2.19) 
Eats Fastfood 1            
2            
3 
0.68 (0.32-1.46)              
0.83 (0.57-1.20)              
1.09 (0.69-1.70) 
Exercise Intensity (Moderate vs. Low) 
                                                                  
Exercise Intensity (High vs. Low) 
1            
2            
3            
1            
2            
3 
0.69 (0.30-1.57)              
0.99 (0.65-1.50)              
1.13 (0.68-1.89)              
0.80 (0.36-1.77)               
1.04 (0.68-1.58)               
1.05 (0.63-1.77) 
Weight Cycling (occasional vs. non)               
 
Weight Cycling (frequent vs. non) 
1            
2            
3            
1            
2            
3 
0.68 (0.27-1.71)              
0.40 (0.23-0.69)*            
1.24 (0.62-2.48)               
0.34 (0.12-0.99)*            
0.19 (0.11-0.34)*            
0.90 (0.44-1.85) 
* OR significant at p < 0.05.                                                                                                
** All group comparisons are performed against the high-risk, Group 4.                                                                     
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Table 7: Factors associated with BMI Category stages 
Variable  Group Odds Ratio Estimates 95% Wald 
Confidence Limits  
Sex (Male vs. Female) 
 
1 
2 
3 
0.48 (0.37-0.63)* 
1.15 (0.89-1.50)  
1.23 (0.95-1.61) 
Race (Black vs. White) 
 
1 
2 
3 
0.16 (0.12-0.21)* 
0.30 (0.23-0.39)* 
0.48 (0.36-0.62)* 
Age 
 
1 
2 
3 
1.06 (1.03-1.10)* 
1.08 (1.04-1.12)* 
1.00 (0.96-1.04) 
Education (HighSchool (HS) vs. No HS)                 
 
 
Education (College + vs. No HS) 
 
1
2 
3 
1 
2 
3 
1.16 (0.74-1.81) 
1.37 (0.86-2.17) 
1.43 (0.89-2.27) 
2.39 (1.43-4.00)* 
2.08 (1.22-3.54)* 
1.66 (0.96-2.85) 
Smoking (Former vs. Non-Smoker)                                                                                                     
 
 
Smoking (Current vs. Non-smoker) 
 
1
2 
3 
1 
2 
3 
1.94 (1.32-2.84)*
1.60 (1.09-2.35)* 
1.45 (0.98-2.16) 
1.58 (1.21-2.08)* 
1.02 (0.78-1.35) 
0.92 (0.69-1.22) 
Currently On Diet  1 
2 
3 
0.34 (0.22-0.51)* 
0.49 (0.33-0.74)* 
0.77 (0.53-1.11) 
Ever Diet 1 0.17 (0.13-0.23)* 
79 
 
2 
3 
0.27 (0.20-0.36)* 
0.43 (0.32-0.58)* 
Eats Fastfood 1 
2 
3 
0.62 (0.48-0.80)* 
0.78 (0.60-1.01) 
0.99 (0.76-1.28) 
Exercise Intensity (Moderate vs. Low) 
 
 
Exercise Intensity (High vs. Low) 
1 
2 
3 
1 
2 
3 
1.12 (0.85-1.49) 
1.20 (0.91-1.60) 
1.22 (0.92-1.64) 
1.64 (1.23-2.20)* 
1.39 (1.04-1.86)* 
1.43 (1.06-1.92)* 
Weight Cycling (occasional vs. non)               
 
 
Weight Cycling (frequent vs. non) 
1 
2 
3 
1 
2 
3 
0.21 (0.15-0.31)* 
0.31 (0.21-0.46)* 
0.49 (0.33-0.73)* 
0.07 (0.05-0.11)* 
0.13 (0.09-0.21)* 
0.28 (0.20-0.43)* 
* OR significant at p < 0.05.                                                                                                
** All group comparisons are performed against the high-risk, Group 4.                                                                     
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Figure 8: Trajectory Modelling of BMI Categories 
 
 
Figure 9: Trajectory Modelling of Continuous BMI  
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